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Abstract 
Asthma  is  a  common  and  complex  inflammatory  disease  of  the  airways 
characterized  by  deregulated  immune  responses  that  involves  activation  of 
multiple  cell  types  including  Th2  cells,  IgE  producing  B cells,  mast  cells, 
basophils  and  eosinophils  as  well  as  resident  lung  cells  such  as  epithelial, 
smooth muscle cells and macrophages. Despite intensive research, there are 
still unmet needs in the treatment of asthma. Recently, a new cytokine of IL 1 
family,  named  IL 33  emerged  as  a  potentially  important  factor  in  the 
immunopathogenesis  of  allergy  and  asthma.  It  was  recently  shown  in  our 
laboratory  that  intranasal  administration  of  IL 33  can  induce  certain 
physiological features that are characteristic of experimental asthma, such as 
eosinophilic  inflammation,  Th2  cytokine  and  antibody  production  as  well  as 
increased airway hyperresponsiveness. 
The effect of IL 33 on the activation and differentiation of allergen specific Th2 
cells has been well studied. However, the contribution of IL 33 to the activation 
of  lung  resident  and  inflammatory  innate  cells  remains  undefined.  In  this 
project I focused on alveolar macrophages and eosinophils as both cell types 
were reported to express IL 33R, ST2L and are thought to play a crucial role in 
asthma pathogenesis. 
I  raised  the  hypothesis  that  IL 33  released  locally  in  the  lungs  may  trigger 
symptoms  resembling  asthma  through  the  activation  of  airway  alveolar 
macrophages.  Furthermore,  I  hypothesize  that  IL 33  may  exacerbate  and 
maintain inflammation in the lungs by the direct activation of eosinophils.    3 
In  our  previous  study  we  showed  that  IL 33  could  switch  the  quiescent 
phenotype  of  alveolar  macrophages  toward  the  alternatively  activated 
phenotype  (M2,  AAM).  In  the  first  part  of  my  thesis  I  looked  at  the 
consequences of this phenomenon for airway inflammation. Using clodronate 
liposomes in vivo I was able to eliminate macrophage population from the lungs 
and  demonstrated  that  resident  alveolar  macrophages  are  crucial  for  the 
development of IL 33 induced eosinophilic inflammation in the airways. I then 
examined the contribution of IL 13, a known M2 differentiation factor, to airway 
inflammation. Using anti IL 13 neutralizing antibodies I showed that IL 13 is 
required for the IL 33 triggered differentiation of alveolar macrophages toward 
M2 phenotype as well as for eosinophilic inflammation. 
Next,  I  looked  at  how  IL 33/ST2  pathway  modulates  the  differentiation  and 
activation  of  eosinophil.  I  demonstrated  that  bone  marrow  hematopoietic 
progenitors CD117
+ express ST2L and that IL 33 is able to differentiate these 
cells toward eosinophils. By employing deficient mice or neutralizing antibodies 
I found that this process is ST2 and IL 5 dependent and independent of IL 13. 
I then extended my research interests to include mature mouse and human 
eosinophils. I showed that both human and mouse resting eosinophils express 
low  levels  of  ST2L  which  can  be  markedly  increased  by  IL 33.  Moreover,  I 
demonstrated  that  eosinophils  that  are  recruited  to  the  lungs  during 
experimental  allergic  airway  inflammation  express  high  levels  of  ST2L. 
Furthermore, I carried out a study on effector function of eosinophils. I found 
that IL 33 induces IL 13, IL 6 and increases TARC, TGF b production by mouse 
eosinophils.  In  addition,  IL 33  exacerbated  IgG induced  human  and  mouse   4 
eosinophil degranulation, likely by enhancing FcgRII expression. Having shown 
earlier  that  IL 13  is  requited  for  the  polarization  of  alveolar  macrophages 
toward  AAM  by  IL 33  in vitro  and  in  light  of  the  fact  that  IL 33 stimulated 
eosinophils can be a significant source of IL 13; I went on to investigate the 
interaction between macrophages and eosinophils. Using co cultures of ST2
 /  
macrophages  with  WT  eosinophils  in  Transwell  system,  I  demonstrated  that 
IL 33  but not IL 5 activated eosinophils can support macrophage polarization 
toward the pro inflammatory AAM phenotype, partially through the production 
of IL 13. 
Finally,  given  the  role  of  IL 33/ST2L  axis  in  eosinophil  activation  in vitro,  I 
investigated  the  contribution  of  IL 33 activated  eosinophils  to  airway 
inflammation  in vivo.  Using  adoptive  transfer  protocol  I  showed  that  the 
contribution of IL 33 activated eosinophils to airway inflammation is mediated 
primarily by the release of cytokines from these cells which, in turn, recruits 
other  inflammatory  cells  and  supports  the  differentiation  of  alveolar 
macrophages towards AAM. 
These data show that IL 33/ST2 pathway regulates multiple features of alveolar 
macrophage  and  eosinophil  biology  that  can  have  a  significant  impact  on 
asthma pathophysiology in the airways. Studies carried out in our laboratory 
and  elsewhere  suggest  that  IL 33  is  equally  capable  of  activating  other  cell 
types that  have been implicated  in  asthma pathology such as Th2, B1 cells, 
DCs,  mast  cells  and  basophils.  Therefore,  targeting  IL 33/ST2  pathway  may 
potentially offer a promising therapeutic approach to asthma and allergy.    5 
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1.1.  Interleukin-33 
A  cytokine  interleukin 33  (IL 33,  IL 1F11)  as  it  is  now  called,  was  initially 
reported  as  a  clone  DVS27  gene  product,  highly  upregulated  in  canine 
vasospastic cerebral arteries after subarachnoid hemorrhage (2). Then, in 2003, 
the same sequence was described as a nuclear factor present in endothelial 
cells  of  high  endothelial  venules  (HEVs)  of  secondary  lymphoid  organs 
(HEVECs),  namely  human  lymph  nodes,  tonsils  and  Peyers's  patches  and 
referred to as NF HEV (3). However, apart from the suggestion by the authors, 
that NF HEV can help controlling the specialized HEV phenotype there was a 
paucity of data on the role of the protein. 
In  2005  Schmitz  and  colleagues  used  a  molecular  profile  based  on  the 
properties of already known IL 1 cytokine family members to search genetic 
sequence databases (4). They established that NF HEV molecule was in fact a 
member of  IL 1  cytokine  superfamily  and  shared  many  molecular  properties 
with several closely related cytokines, such as IL 1a/b (IL 1F1/IL 1F2), IL 1Ra 
(IL 1F3),  and  IL 18  (IL 1F4).  As  a  newly  identified  member  of  IL 1 like 
cytokines, NF HEV was renamed to IL 33 (IL 1F11) . 
1.1.1.  Structure and molecular properties of IL-33 
Schmitz et al. matched IL 33 to its specific receptor, a protein known as orphan 
receptor  T1/ST2  (IL 33Ra)  which  will  be  discussed  in  detail  in  a  separate 
chapter  (4).  These  authors  found  the  human  IL 33  gene  to  be  located  on 
chromosome 9 in 9p24.1 region, while its murine counterpart was mapped to 
chromosome 19qC1 region. The lengths of IL 33 encoding cDNA sequences are   22 
similar: in humans a full length IL 33 protein (pro IL33) of 30 kDa molecular 
mass  is  constituted  by  270  amino acids  while  its  murine  counterpart  is  266 
amino acid in length and forms a 29.9 kDa protein. At the amino acid level the 
two  proteins  share  55%  of  the  sequence.  Moreover,  by  aligning  amino  acid 
sequences of human and murine mature IL 33 with members of the IL 1 family, 
Schmitz  and  colleagues  demonstrated  that  both  IL 33  proteins  share 
12 b strands  that  make  up  the  characteristic  b trefoil  fold,  a  structure  first 
described in IL 1 by Priestle et al (5). Phylogenetic tree analysis revealed that 
among other known IL 1 family members IL 33 is most closely related to IL 18 
(IL 1F4). In contrast to other family members neither of the two cytokines is 
linked to the IL 1 gene cluster on human chromosome 2. 
The  structure  of  IL 33  suggests  that  it  has  the  capacity  to  act  both  as  a 
cytokine and as a nuclear factor. Indeed, unlike most other members of the 
IL 1 family of cytokines, with one exception for IL 1a, IL 33 is often found in 
the nucleus rather than cytoplasm (3, 6 7). In humans, it is commonly localized 
in nuclei of epithelial and endothelial cells (3, 6, 8) while in mouse it has also 
been shown to have affinity for chromatin of bone marrow derived mast cells 
in vitro (9). Its nuclear localization is mediated by a nuclear localization signal in 
its N’ terminus (NLS), while chromatin binding capabilities are facilitated by a 
homeodomain  (helix turn helix like  motif)  (10 11),  which  presents  close 
homology  to  LANA  (latency associated  nuclear  antigen),  a  protein  coded  by 
Kaposi’s  sarcoma associated  herpesvirus  (11).  The  other  portion  of  IL 33 
protein at the carboxyl terminus is a cytokine domain formed by 12 bstrands as 
mentioned above, called the IL 1 like domain. Apart from the fact that IL 33   23 
can  bind  to  the  acidic  residues  of  a  dimeric  histone  (H2A H2B)  thereby 
suppressing gene transcription in vitro, the role for IL 33 as a nuclear factor 
remains obscure (11). 
1.1.2.  IL-33 processing 
Similar to other members of IL 1 family, such as IL 18 and IL 1b, IL 33 lacks 
signal peptide at the N’ terminus that is required for a successful assembly via 
the  endoplasmic  reticulum  and  transport  through  the  Golgi  apparatus  (4). 
However,  despite  early  predictions  IL 33  differs  considerably  from  the  two 
cytokines in the way that it is cleaved by proteases. Although in vitro studies 
showed that IL 33 can be processed by caspase 1 from pro IL 33 30 kDa down 
to what was originally assumed to be an active mature form of 20 22kDa, the 
reaction is rather inefficient, when compared with the cleavage of IL 1b (12 
14), and does not occur in the environment devoid of other proteases (14). 
Even when cells were modified by introducing mutations carrying a potential 
caspase 1 binding site for the IL 33 to be expressed, the 30kDa pre IL 33 was 
still  dominant.  However,  studies  by  other  groups  showed  that  the  cleavage 
could  be  prevented  by  using  a  specific  caspase 1  inhibitor  (4,  12).  It  was 
suggested that the activation of the NLRP3 inflammasome with alum adjuvant 
in vivo  activates  caspase 1  which,  in  turn,  cleaves  pro IL 33  allowing  for  its 
secretion  (15).  The  mature  form  of  IL 33  can  also  be  produced  by 
calpain mediated  cleavage  (16).  Interestingly,  experiments  showed  that 
proteases  that  are  activated  during  cell  apoptosis,  such  as  caspase 7  and 
caspase 3 could do the cleavage (12 13, 17). These apparently conflicting data 
may be partially explained by the observation that pro IL 33 lacks a classical   24 
caspase 1 binding site (Derek Gilchrist, unpublished data). Instead, it contains 
cleavage  sites  for  caspase 7  and  caspase 3  are  located  within  its  IL 1 like 
domain  (cytokine  domain).  Therefore  it  is  possible  that  pro IL 33  is  not  a 
primary target for caspase 1. Rather, the protein is actually processed by other 
proteases  that  are  controlled  by  caspase 1.  The  important  point  is  that  the 
maturation  process  facilitated  by  caspases  renders  the  IL 33  biologically 
inactive. 
1.1.3.  Secretion of IL-33 
There are limited and inconclusive data available about how IL 33 is released. It 
was shown that IL 33 is released by human acute monocytic leukemia cell line 
(THP 1)  upon  stimulation  with  alum  adjuvant,  lypopolysaccharide  (LPS),  LPS 
with  alum,  or  upon  infection  with  Listeria  moncytogenes  and  Salmonella 
typhimurium  (14 15).  Stimulation  with  a  known  cell  activator  PMA  (phorbol 
12 myristate  13 acetate)  was  reported  to  induce  IL 33  secretion  from  rat 
cardiac fibroblasts (18). Supporting data was also  obtained in mixed murine 
glial cells cultured in the presence of LPS and ATP (19).  
Recently, an alternative mechanism for IL 33 release through cell necrosis has 
been proposed that takes into account the indirect nature of IL 33 processing 
by caspases as well as the primarily nuclear localization of a full length protein 
in vivo  (6,  10).  This  notion  stems  from  the  observation  that  IL 33  harbours 
structural  elements  very  similar  to  those  found  in  IL 1a  and  so called 
high mobility group  box 1  (HMGB1).  The  latter  is  a  nuclear  factor  with 
transcription suppressing  capabilities  commonly  found  in  the  nucleus  and  is   25 
only  released  through  cell  necrosis  when  it  contributes  locally  to  the 
inflammatory processes at sites of tissue damage (20 22). Although HMGB1 is 
effectively acting as a potential danger signal associated with tissue damage, it 
is  rendered  inactive  by  the  caspase dependent  processes  associated  with 
apoptosis  (23).  In  this  case  it  contributes  to  the  apoptotic  cell mediated 
tolerance.  The  necrosis associated  mechanism  of  IL 33  release  is  consistent 
with  its  postulated  role  as  a  novel  ‘alarmin’.  By  definition,  alarmins  are 
extra cellular mediators that serve as an endogenous, ‘danger signal’, designed 
to be released immediately upon and as a direct result of tissue damage or 
pathogens breaching the epithelial barriers. It is possible that IL 33 may be part 
of  such  warning  system  by  complementing  signals  from  so called 
pathogen associated molecular pattern receptors (PAMPs), such as TLR family, 
or NOD like receptor protein family (nucleotide binding oligomerization domain 
(24 25). If so, the release mechanism through cell necrosis may actually be the 
primary one, while the caspase dependent mechanism, which renders mature 
IL 33  biologically  inactive  (12 13)  may  be  used  during  steady  state  tissue 
turnover where there is no need for triggering inflammation and mounting a 
defence response. 
Taken  together,  it  seems  that  the  truncated  form  of  IL 33  is  inactive  as  a 
cytokine and released during apoptosis, while the immature (proIL 33) form of 
the  protein  is  released  during  cell  necrosis  and  may  act  as  an  endogenous 
‘alarmin’.   26 
1.1.4.  Expression pattern of IL-33 in homeostasis and disease 
The list of cellular sources of IL 33 seems to be consistent with the proposed 
role  of  IL 33  as  an  alarmin.  The  cytokine  is  predominantly  expressed  in 
structural lining cells that act as a primary defence mechanism against invading 
pathogens.  IL 33  can  be  found  across  the  vascular  system,  particularly  in 
endothelial cells of high endothelial venules (HEV cells), but also in large and 
small vessel endothelial cells, including liver, colon, small intestine, stomach, 
kidney, prostate, skin and skeletal muscles (6, 8) where it is commonly mapped 
to the nucleus. Another common location for IL 33 protein is the epithelial cells 
of many organs, including stomach, tonsilar crypts, salivary glands, skin, and 
lung  tissue  (6,  26).  IL 33  protein  expression  can  be  markedly  elevated 
compared to steady state at several locations under pathologic conditions which 
includes lung epithelial cells and smooth muscle cells of asthmatic patients (26 
28),  skin  from  atopic  dermatitis  patients  (29),  brain  of  Alzheimer’s  disease 
patients, pancreatic myofibroblasts of chronic pancreatatis patients (30), colon 
of ulcerative colitis patients (31), and synovium of rheumatoid  arthritis  (RA) 
patients  (6 7,  32).  In  inflammatory  arthritis  model,  TNF a  and  IL 1b  are 
thought to be responsible for IL 33 upregulation (7). 
Although full length, nuclear IL 33 protein was found constitutively expressed in 
resting blood vessel endothelium, the expression is rapidly down regulated on 
the onset of tumor  or wound healing associated angiogenesis, compared to 
vessels  in  healthy  tissue.  Some  in vitro  experiments  strongly  suggest  that 
nuclear IL 33 expression can only occur during cell cycle arrest. However, the 
non proliferatory status alone was not sufficient to restore the level of nuclear   27 
IL 33  that  could  be  detected  by  immunohistochemistry.  This  required  an 
additional  cell  contact  inhibition  signal  that  in vivo  may  come  from  spatial 
restrictions in densely packed endothelial cells of healthy vasculature. Similar 
cell to cell  signal  could  be  generated  in  super confluent  endothelial  cell 
monolayers in vitro, as shown in HUVEC cultures. Consistently, nuclear IL 33 
was  scarcely  detectable  (or  not  at  all)  in  immature  blood  vessels  of  human 
tumours which are highly angiogenic (8). In contrast, another study concluded 
that long, immature form of nuclear IL 33 protein is abundant in many human 
tumours, as well as in normal tissues, making it suitable for use as a general 
nuclear marker of endothelial cells (6). This apparent discrepancy still awaits to 
be explained as tumour tissues, owing to their high proliferation status, tend to 
become hypoxic which, on its own, should enhance nuclear IL 33 expression 
(Neal Millar, personal communication), unless the inhibition caused by VEGF can 
counteract  the  effect  of  hypoxia.  Interestingly,  as  a  cytokine,  IL 33  induces 
both angiogenesis and vaso permeability, which is similar to what VEGF does. 
Furthermore, IL 33 increases the endothelial cell proliferation, migration, and 
tubular network formation comparable with VEGF in vitro. Consistently, IL 33 
promoted vessel sprouting and neovascularization in mice in vivo, as well as the 
proliferation, migration, and morphologic differentiation of human endothelial 
cells in vitro, apparently by stimulating endothelial NO production (33). Given 
the distinct roles of nuclear and released forms of other cytokines, such as IL 1, 
similar  effect  may  occur  in  endothelial  cells  expressing  IL 33.  However,  the 
precise contribution of both forms of IL 33 to the regulation of angiogenesis 
and homeostatic tissue turnover awaits further clarification.   28 
In terms of IL 33 expression on transcriptional level, IL 33 mRNA is ubiquitously 
expressed across many tissues and can be detected virtually at any location in 
human  and  murine  systems.  To  date,  the  only  major  organ  in  which  IL 33 
mRNA was not detected is human spleen, although IL 33 message was found in 
mouse  spleen  tissue  (4),  as  well  as  in  mouse  splenic  dendritic  cells  upon 
stimulation with LPS. 
1.1.5.  IL-33 signaling via ST2L and IL-1RAcP complex 
In 2005 Schmitz et al. (4) identified that so called “orphan receptor”, T1/ST2 
(or IL 1R4, now also called IL 33Ra), a molecule known for sixteen years, is a 
receptor for IL 33 (IL 1F11). This was soon supplemented by the observation 
that another molecule, IL 1R accessory protein (IL 1RAcP), is required in the 
formation of a fully functional IL 33 receptor complex (34 35). In fact, IL 1RAcP 
is  widely shared  between  several  other  IL 1 related  cytokines,  namely  IL 1a 
(IL 1F1),  IL 1b  (IL 1F2),  IL 1F6,  IL 1F8  and  ILF 9,  to  form  heterodimer 
receptor complexes with the respective alpha chains that assure single cytokine 
specificity of the receptor complexes they  constitute. The  expression of ST2 
gene  can  produce  two  major  splice  variants  of  ST2  mRNA,  the  membrane 
bound  form,  ST2L,  and  truncated  soluble  form,  sST2.  Each  splice  variant  is 
controlled by a pair of distinct promoters (36). Also, alternate splicing variants 
(ST2LV  and  sST2V)  were  reported  in  humans  and  chickens  (37 38).  The 
membrane bound  ST2L  is  required  for  mediating  IL 33  signaling,  whereas 
soluble sST2 acts as a decoy receptor by masking IL 33 biologic activity (39 40) 
in  a  similar  fashion  that  soluble  IL 1R  does  to  IL 1  signaling.  IL 33  binds 
specifically  to  ST2L  and  does  not  cross react  with  any  other  IL 1R  related   29 
receptors (4, 41 42). Both ST2L and IL 1RAcP are necessary for IL 33 action as 
mice deficient either for IL 1RAcP or ST2 are completely unresponsive to IL 33 
administration while wild type animals exhibit a marked inflammatory reaction 
(35, 43). Consistently, it was demonstrated that soluble IL 1RAcP enhances the 
ability of soluble ST2 to inhibit IL 33 signaling (42). 
Several recent studies demonstrated that IL 33 generated signal can also be 
regulated through the binding of IL 33 to an alternate receptor complex that 
consists of ST2L and so called single Ig IL 1 related molecule (SIGIRR), also 
referred to as Toll IL 1R8 (TIR8) (44). This molecule has been implicated to be 
a negative regulator of Toll like receptor (TLR)  and IL 1R mediated immune 
responses  (45).  SIGIRR deficient  dendritic  cells  exhibit  increased 
responsiveness to the stimulation with TLR ligands as well as IL 1 and IL 18 
(46)  and  SIGIRR deficient  Th2 cells  showed  a  more  abundant  expression  of 
Th2 associated cytokines in response to IL 33 (44). These data suggest that 
SIGIRR/ST2L receptor complex may function as a negative regulator of IL 33, 
similarly to sST2 decoy receptor. 
The  membrane  bound  IL 33  receptor,  ST2L  contains  common  intercellular 
domain  called  Toll IL 1R  (TIR)  domain,  which  is  shared  among  the  entire 
TLR/IL 1R  receptor  superfamily.  It  was  demonstrated  that  TIR  domain  of 
IL 1RAcP directly interacts with the TIR domain of ST2L/IL 33 and contributes 
to  facilitating  the  IL 33 mediated  signal  (35).  Downstream  of  the 
IL 33/ST2L/IL 1RAcP  complex,  IL 33  signal  is  passed  on  by  several  adapter 
molecules, most of which being commonly used by other members of IL 1R 
family. Schmitz et al. showed that IL 33 binding triggers the recruitment of the   30 
myeloid  differentiation  primary response  protein 88  (MyD88),  and  TNF 
receptor associated factor (TRAF6) to TIR domain in the cytoplasmic portion of 
ST2L (and IL 1RAcP) where the molecules are activated (4). The involvement of 
protein MyD88 adaptor, but not TRIF, was found indispensable for ST2L/IL 33 
signaling,  both  in vitro  (43,  47)  and  in vivo  (48).  Downstream  of 
TIR/MyD88/TRAF6  interactions,  a  cascade  of  phosphorylation  includes 
IL 1R associated kinase 1 (IRAK1) and IRAK4, which eventually leads to the 
activation of all three mitogen activated protein kinases (MAP kinases) and a 
transcription factor called nuclear factor kB (NF kB) in T cells and mast cells (4, 
43).  Consistently,  Schmitz  et  al.  demonstrated  that  Erk1/2,  p38  and  NF kB 
activation  can  be  blocked  in  the  presence  of  anti ST2  antibody  in vitro  (4). 
Furthermore,  the  detailed  analysis  of  IL 33 induced  mast  cell  activation 
revealed  that  IL 33  triggers  NF kB  phosphorylation  by  intracellular  calcium 
mobilization mediated by phospholipase D and sphingosine kinase 1 (29). 
As  mentioned  above,  IL 33  can  also  signal  entirely  independent  of  Ca
2+  in 
which case a phosphorylation cascade of MAP kinases is triggered, including 
Erk1/2, p38 and JNK, that results in the activation of transcription factor called 
activator protein 1 (AP 1) (4, 29, 43). Interestingly the IL 33 induced activation 
of p38, JNK and NF kB depends on TRAF6 phosphorylation, while ERK can be 
activated in a TRAF6 independent fashion as demonstrated in mouse embryonic 
fibroblasts  (MEFs)  (49).  Both  pathways  (NF kB  and  MAP  kinases)  can  be 
regarded  as  complementary  to  one  another  in  a  sense  that  each  facilitates 
some  of  the  responses,  but  not  the  others.  For  example,  in  T cells  IL 33 
mediates the production of IL 5 and IL 13 via different mechanisms: whereas   31 
the IL 33 induced IL 5 expression could be suppressed by specific inhibitors of 
p38, ERK1/2 and JNK1/2 but not the inhibitor of NF kB, the expression of IL 13 
was suppressed by p38, NF kB and, to a lesser extent, by ERK1/2 and JNK1/2 
inhibitors. Also, it was recently shown that IL 33 mediated the production of 
IL 1b,  IL 3,  IL 6,  TNF a,  MIP 1a  (CCL3),  MIP 2a  (CXCL2),  MCP 1  (CCL2), 
prostaglandin  D2  leukotriene  B4,  and  triggered  degranulation  in  IgE primed 
human and murine mast cells in an NF kB dependent manner. In contrast, the 
production  of  IL 5,  IL 13,  Eotaxin 2  (CCL24),  RANTES  (CCL5)  and  TARC 
(CCL17)  was  mediated  by  MAPK  pathway  and  was  essentially 
NF kB independent (29). 
1.1.6.   The role of IL-33 in type 1 immune responses 
1.1.6.1.  Rheumatoid arthritis 
Based on the postulated role for IL 33 as a novel alarmin, one can predict that 
the levels of IL 33 are likely to be elevated at sites of high burden of cell death 
and that its function may be modulated by local milieu of cellular mediators. 
Indeed,  elevated  levels  of  IL 33  have  been  reported  in  patients  with 
Th1/Th17 driven  autoimmune  diseases  (7,  50).  IL 33  and  its  receptor  have 
been specifically mapped to disease affected tissues   synovial fluid (51) and 
synovium  of  RA  (7)  and  in  skin  lesions  of  psoriatic  patients  (52).  In vitro 
analysis  points  at  synovial  fibroblasts  as  a  possible  source  of  IL 33  in  RA 
synovium as they markedly up regulate IL 33 expression upon TNF a or IL 1b 
stimulation, both of which are hallmark cytokines in the immunopathogenesis of 
RA (7). Further evidence for the stromal expression of IL 33 comes from hTNF   32 
transgenic  mice  that  show  abundant  IL 33  expression  in  the  bone  and 
cartilage invading  synovium  (Dr  M.  Kurowska Stolarska,  personal 
communication).  Studies  on  ST2 deficient  mice  revealed  that  IL 33/ST2 
pathway  is  required  for  the  development  of  both  cellular  and  humoral 
autoimmunity as well as chronic articular inflammation in arthritis. ST2 deficient 
mice developed significantly attenuated collagen induced arthritis manifested by 
lower incidence and severity score. This was associated with lower levels of 
collagen specific  antibodies  detected  in  sera  and  inhibited  production  of 
pro inflammatory cytokines such as IFN g, IL 17 and TNF a by draining lymph 
node  cells  and  by  articular  tissue.  A  study  on  the  mechanism  behind  this 
process  revealed  that  IL 33 triggered,  mast  cell derived  IL 1  and  IL 6  are 
responsible for shifting the balance of T cell response toward pathogenic Th17 
and Th1 (7). 
1.1.6.2.   Atherosclerosis and obesity 
Recently, IL 33/ST2 has been identified as a crucial pathway in adipose tissue 
biology. This is especially interesting in light of a current hypothesis that links 
adipose  tissue  immune  status  to  glucose  homeostasis.  It  is  believed  that 
adipose tissue infiltration by Th1 cells and pro inflammatory macrophages (also 
known  as  M1)  results  in  obesity  and  obesity induced  metabolic  damage. 
Conversely,  Th2   and  Treg derived  cytokines  and,  most  importantly,  the 
alternatively activated macrophages (AAM, also known as M2 macrophages) are 
protective factors against obesity and type 2 diabetes (53). It was found that 
IL 33 is expressed in human adipose tissue predominantly in adipocytes and 
pre adipocytes  (54).  Furthermore,  IL 33R  is  expressed  by  adipose  tissue   33 
macrophages  and  adipocytes  themselves  (55).  Mature  mice  deficient  in  ST2 
have an enhanced weight gain and more adipose tissue compared to WT mice 
while on a high fat diet suggesting that the endogenous IL 33/ST2 pathway 
plays a beneficial role in glucose homeostasis. Ex vivo treatment of epididymal 
stromal vascular fraction (eSVF) containing pre adipocytes with IL 33 caused 
the inhibition of lipid accumulation that was associated with reduced expression 
of genes linked to lipid metabolism and adipogenesis. Most importantly, IL 33 
decreased  the  expression  of  resistin  a  mediator  that  is  responsible  for 
development of insulin resistance and type 2 diabetes. Administration of IL 33 
has  a  protective  effect  on  body  composition  and  glucose  homeostasis  by 
decreasing body fat, adipocytes size and total serum cholesterol. Obesity is also 
an  independent  risk  factor  for  the  development  of  chronic  inflammation  of 
arterial wall (atherosclerosis) which can eventually cause myocardial infraction 
and stroke. The development of atherosclerosis involves a complex interaction 
between  vascular  endothelium,  serum  lipids,  inflammatory  macrophages, 
Th1 cells, platelets and vascular smooth muscle cells (56). Recently, it has been 
found  that  the  IL 33/ST2  pathway,  in  addition  to  being  protective  against 
adipose  tissue  inflammation,  also  protects  against  atherosclerosis.  IL 33  is 
expressed in normal and atherosclerotic vasculature of mice deficient in ApoE, a 
protein essential for the transport and metabolism of lipids. Administration of 
IL 33 to ApoE
 /  mice on a high fat diet reduced the size of the atherosclerotic 
lesion.  The  underlying  mechanism  of  this  protective  effect  of  IL 33  against 
atherosclerosis  and  obesity  is  the  ability  of  IL 33  to  trigger  type 2  immune 
responses  such  as  Th2  cytokine  production  and  AAM  (M2)  macrophage   34 
differentiation  as  originally  reported  by  Kurowska Stolarska  et  al  (26)  and 
described in detail in chapter 1.2.2. 
1.1.7.  The role of IL-33 in type 2 immune responses 
1.1.7.1.   Asthma and murine airway inflammation models 
Asthma  is  a  complex  and  heterogeneous  disease  which  is  characterized  by 
chronic inflammation of the airways associated with variable airflow obstruction 
arising  from various  genetic  and  environmental  factors  (57 58).  The  disease 
stems from an individuals hyper response to innocuous environmental antigens 
that with time may lead to marked histlogical changes that can compromise 
lung function. This disproportional immune response to allergens is mediated by 
CD4
+ T helper 2 cells, eosinophils, mast cells, neutrophils, macrophages, and 
IgE antibodies. The pathophysiology of asthma includes mucus hyper secretion, 
bronchial hyper responsiveness and smooth muscle hypertrophy and thickening 
of the epithelial basement membrane (57, 59). 
There are several lines of evidence that IL 33 is an important effector cytokine 
in asthma and allergy. IL 33 is expressed more abundantly in asthma patients 
compared to healthy individuals, which could be detected systemically in sera 
from affected individuals (60). However, the primary source tissue is thought to 
be the lung epithelial cells (26) and smooth muscle cells (27) which, owing to 
their localization in pulmonary mucosal barrier, may readily respond to a variety 
of environmental stimuli. Recently, Genome Wide Association Studies (GWAS) 
identified several single nucleotide polymorphisms (SNPs) within IL 33 and ST2 
coding genes that are more frequent in asthma sufferers compared to healthy   35 
subjects. These findings may represent the first step toward understanding the 
genetic mechanisms responsible for allergy and asthma (61 63). Moreover, in 
the ovalbumin (OVA) induced murine asthma model of airway inflammation the 
levels of both soluble ST2 and IL 33 mRNA are markedly elevated in sera and 
lung  tissues  respectively  (41,  43,  64).  In  addition,  the  administration  of 
exogenous IL 33 into lungs, leads to asthma like phenotype (43, 48). 
Numerous in vivo studies allowed for a fairly detailed investigation into the role 
of  ST2/IL 33  pathway  in  allergy  and  asthma  pathology.  Those  which  used 
ST2 deficient animals demonstrate that permanent lack of IL 33 signaling can 
markedly attenuate key inflammatory responses such as BAL fluid eosinophilia, 
macrophage count and levels of IL 5, Eotaxins (CL11 and CCL24) and TARC 
(CCL17), together with pulmonary inflammation, while BAL fluid expression of 
IL 4 and IL 13 did not change, compared to BALB/c mice (26, 43). Serum IgG1 
and IgE levels were also normal (43). This outcome was reproducibly obtained 
in  so called  acute  airway  inflammation  model  with  a  single  OVA/alum 
sensitization, followed by three challenges on day 8, 9 and 10, with analysis on 
day 12 (43). However, if a model that involves two sensitizations (12 to 14 days 
apart) was investigated, most of the responses in ST2 deficient animals were 
similar to those in BALB/c mice (43, 65 66). These data suggest that, at least in 
animal  models  of  asthma,  the  contribution  of  IL 33/ST2  pathway  is 
indispensable in the acute phase of the antigen driven responses, whereas in 
the  chronic  phase  it  can  be  compensated  for  by  different  inflammatory 
pathways.   36 
Several groups assumed a different approach at investigating the role of the 
ST2/IL 33  pathway  in  asthma  models  and  employed  various  techniques  to 
transiently disrupt IL 33 signal, such as  the  use  of anti ST2 antibody (clone 
E310) (67 68), anti IL 33 antibody (69), or soluble ST2 Fc fusion protein (64). 
Regardless of which particular technique was used to transiently block IL 33 
signal the differences include reduced eosinophil count and IL 5 levels detected 
in BAL fluid (64, 67, 69), reduced IL 4 in BAL fluid (64, 68 69), lower levels of 
IL 13 detected in BAL fluid, as well as systemically reduced OVA specific IgE 
levels  (67,  69),  reduced  airway  hyper responsiveness,  mucus  secretion  and 
ST2
+ cell infiltration in lungs (68), and reduced pulmonary inflammation (69). 
Thus, these studies confirmed the results obtained from ST2 deficient mice. 
While  IL 33  acts  on  many  different  cell  types  in  experimental  asthma,  the 
contribution  of  ST2/IL 33 activated  T cells  is  among  the  most  extensively 
studied aspects of the disease. By means of adoptive transfer of Th2 cells it 
was  demonstrated  that  the  response  to  OVA  in  recipient  animals  that  had 
received either anti ST2 antibody or ST2 IgG fusion protein is diminished, as 
reflected  by  reduced  eosinophil  numbers,  reduced IL 4  and  IL 5,  as  well  as 
IL 6, IL 13 levels in BAL fluid (67, 70), while levels of IL 10 and IFN g remained 
unchanged  (67).  Moreover,  it  has  been  demonstrated  recently  that  the 
resolution  of  allergic  inflammation  and  airway  hyperresponsiveness  (AHR) 
depends on the neutralization of ST2/IL 33 pathway in T cells. This suggests 
that Il 33 is necessary not only for the development of allergic response but 
also for its maintenance (68).   37 
In addition, a group from our own laboratory found that in the presence of 
antigen  stimulation  (OVA)  or  anti CD3 antibody,  IL 33  can  potently  drive  a 
subpopulation of CD4
+ cells that produce mainly IL 5 and IL 13 but not IL 4, 
which makes it distinct from the classical Th2 cells (43). Unlike Th2 cells, this 
IL 33 differentiated,  IL 5 producing  sub population  is  entirely  independent  of 
IL 4  as  it  has  been  demonstrated  to  develop  in  IL 4
 /   mice  and,  most 
importantly, could exacerbate OVA induced airway inflammation both in IL 4
 /  
and WT background animals on a similar scale. The key role of IL 33 in the 
activation of those cells is consistent with the fact that IL 33 signaling does not 
induce GATA 3 or STAT6 factors, that classical Th2 cell population depend on. 
Furthermore, it was shown that dendritic cells (DCs) respond directly to IL 33 in 
a ST2 dependent manner and are capable of supporting the development of a 
IL 5
+IL 4
   Th2  cell  subset  (71).  Therefore,  these  studies  provide  a  possible 
mechanism explaining the existence and activation of IL 5 producing T cells in 
IL 4 deficient  mice  in  different  disease  models  (72 76).  In  the  light  of  an 
increasing  interest  in  different  pathological  phenotypes  of  asthma,  further 
clinical studies into the contribution of the classical Th2 versus IL 33 triggered 
IL 4 independent T cells to airway inflammation may provide important insights 
into  the  etiology  of  different  phenotypes  of  asthma,  and  may  offer  a  novel 
therapeutic approach (77). 
Along  with  Th2  activation,  IL 33  strongly  affects  the  innate  arm  of  type 2 
immunity,  causing  splenomegaly,  blood  eosinophilia  and  pulmonary 
inflammation as demonstrated by the administration of IL 33 to naïve mice (4, 
43)  and  later  confirmed  in  transgenic  mice  that  overexpress  IL 33  (78). 
Furthermore, IL 33 was reported to induce goblet cell hyperplasia and massive   38 
mucus  overproduction  in  the  lungs  and  stomach  (4).  Several  groups 
demonstrated that those changes could be attributed to the activation of mast 
cells (29), basophils (79), and epithelial cells (80). For instance, IL 33 is capable 
of mast cell degranulation, independent of T or B cells although it does require 
sustained  exposure  to  IgE.  Furthermore,  IL 33  triggers  the  release  of 
leukotriens (LTB4) and prostaglandin D2 (PGD2) and stimulates mast cells to 
secrete an array of cytokines, such as IL 1b, IL 3, IL 6, TNF a and chemokines, 
such  as  MIP 2a  (CXCL2),  MCP 1  (CCL2)  and  MIP 1a  (CCL3),  in  an  NF kB 
dependent manner. It also induces the release of IL 5, IL 13, and chemokines, 
Eotaxin 2 (CCL24), RANTES (CCL5) and TARC (CCL17), through the MAP kinase 
pathway  and  independent  of  NF kB  (29).  Interestingly,  IL 33  was  found 
substantially elevated in atopic patients during systemic (anaphylactic) shock or 
in atopic dermatitis patients but not in subjects without ongoing inflammation. 
Consistently,  in  the  murine  models  of  systemic  anaphylaxis  the  response  to 
allergen was effectively attenuated by the use of a soluble decoy IL 33 receptor 
(sST2), anti IL 33 antibody or mast cell depletion. Thus, IL 33 appears to be an 
important  molecule  in  the  pathogenesis  of  IgE   and  mast  cell associated 
diseases and may represent a useful target for drugs aimed at preventing an 
anaphylactic shock (29). 
As for the basophils, it was shown recently that IL 33 can act on freshly sorted 
murine  bone  marrow  basophils  without  any  priming  with  IL 3  or  FceR 
cross linking and it stimulates the release of substantial amounts of histamine, 
IL 4 and IL 6 from these cells, thereby mimicking the response to GM CSF, at 
least  in  the  murine  system.  Also,  IL 33  expands  basophil  population  in  the   39 
murine  bone  marrow  in vivo,  through  an  indirect  mechanism  dependent  on 
common b chain that is shared between receptors for IL 3, IL 5 and GM CSF 
(79). 
Human  basophils,  on  the  other  hand,  do  not  express  IL 33  receptor 
constitutively but its expression is IL 3 inducible. Yet, they readily respond to 
IL 33, without prior priming, and the outcome is very similar to that exerted by 
IL 3, namely, the secretion of IL 4, IL 8 and IL 13. However, IL 33 does not 
prime human basophils for C5a triggered LTC4 release (81). 
IL 33 was also shown to promote histamine release triggered by antigen bound 
(cross linked) IgE. Moreover, IL 33 can trigger migratory responses of human 
basophils by inducing CD11b that is thought to regulate their adhesiveness to 
endothelial  cells  thereby  facilitating  basophil  transmigration  from  blood  to 
tissues. Furthermore, it was reported that IL 33 enhanced basophil migration 
along the gradient of Eotaxin (CCL11), although no apparent change in CCR3 
expression was observed (82). 
Taken together, there is growing evidence that IL 33 is one of the important 
factors  that  are  capable  of  modulating  allergic  inflammation  by  skewing  the 
balance  of  adoptive  responses  towards  type 2  and/or  by  acting  directly  on 
several innate cells that contribute to the pathogenesis of lung inflammatory 
disease.   40 
1.1.7.2.   Helminthic infections 
The  process  of  developing  an  effective  immunity  against  helminth  parasites 
depends  upon  the  host’s  ability  to  mount  an  effective  T helper 
type 2 associated cytokine response as well as the activation of innate immune 
cells. Recently, IL 33 joined other type 2 cytokines such as IL 4, IL 9, IL 13, 
IL 25 on a list of essential factors known to facilitate worm expulsion. IL 33 
seems to play a particular role in fighting gastrointestinal helminths, such as 
Trichuris  muris  where it  shifts  the  balance  toward  Th2  cells  producing  IL 4, 
IL 9, and IL 13. Moreover, exogenous IL 33 induced the expression of thymic 
stromal lymphopoietin (TSLP) from epithelial cells of the infected caecum which 
itself  is  important  for  the  generation  of  Th2 driven  parasite  immunity. 
Interestingly,  IL 33  can  also  act  independent  of  T cells,  as  demonstrated  in 
SCID mice by increasing intestinal epithelium cell proliferation and crypt length, 
particularly in the initiation phase of the infection (83).  
More  recently,  by  employing  novel  IL 13 eGFP  reporter  mice  Neill  et  al. 
identified  a  distinct  subset  of  Th2 inducible  innate  effector  cells,  named 
nuocytes  that  may  represent  the  predominant  early  source  of  IL 13  during 
helminth infection with Nippostrongylus brasiliensis. Nuocyte leukocytes expand 
rapidly  in  response  to  IL 33  and  IL 25  and  fail  to  develop  in  the  combined 
absence of these two cytokines causing a severe defect in worm expulsion (84). 
Taken  together,  the  above  data  suggest  that  IL 33  is  essential  for  the 
development  of  immunity  against  helminth  parasites  by  activation  Th2  cells,   41 
epithelial  cells  and  nuocytes.  A  summary  of  IL 33  biology  is  shown  in 
Figure 1.2. 
1.2.  Eosinophil 
Eosinophils have long been considered merely a type of terminally differentiated 
effector cells specialized in host defence against parasite helminths. However, 
there is now growing evidence to support the notion of a much more complex 
role that eosinophils play in the immune system as they seem to be involved in 
both adaptive and innate arms of immunity. 
1.2.1.  Eosinophil development 
Eosinophil differentiation process occurs in the bone marrow and is induced and 
sustained by several cytokines and growth factors. It is now well established 
that  three  closely  related  cytokines,  namely  IL 3,  IL 5  and  GM CSF,  play  a 
major  role  in  controlling  eosinophilopoiesis.  Several  reports  clearly 
demonstrated  that  IL 5  is  the  most  specific  and  most  effective  factor  that 
controls  both  eosinophil  differentiation  and  recruitment  in vivo  (85 88). 
Produced mainly by activated T cells and mast cells, IL 5 exerts its effect in the 
bone  marrow  by  stimulating  the  expansion  of  a  narrow  pool  of 
IL 5Ra expressing  eosinophil  progenitor  (hEoPs)  cells  that  had  differentiated 
under the control of more pluripotent cytokines and growth factors, including 
IL 3,  CM CSF,  stem  cell  factor  (SCF)  and  FMS like  tyrosine  kinase 3  ligand 
(FLT3 L)  (89).  IL 5Ra  expression  is  regarded  a  prerequisite  and  early 
lineage specific event during the course of eosinophilopoiesis (90 91), (Figure 
1.3.).   42 
In  the  human  system,  EoPs  differentiate  from  IL 5Ra
   common  myeloid 
progenitor  (CMP)  cells  (92),  that  were  defined  by  Mori  et  al.  as 
IL 5Ra
+CD34
+CD38
+IL 3Ra
+CD45RA
  expressing
 cells (91), (Figure 1.3.). 
In  the  mouse  system,  eosinophils  originate  from  the  eosinophil 
lineage committed  progenitors  (mEoPs)  which  arise  downstream  of 
granulocyte/macrophage  progenitors  (GMPs)  and  are  CD117
+  (c kit positive) 
cells (Figure 1.3.). Thus, unlike in human hematopoiesis, murine eosinophils, 
neutrophils  and  monocytes  all  originate  from  GMP  cells.  The  precursor  cells 
(mEoPs)  that  give  rise  to  murine  eosinophils  were  defined  as 
(Lineage
 Sca 1
 ) IL 5Ra
+CD34
+CD117
low,  and  are  characterized  by  the 
activation of GATA 1 transcription factor (90). 
Despite  the  fact  that  eosinophil  development  pathways  differ  considerably 
between  the  human  and  mouse  in  regard  to  the  precise  distribution  of 
immediate precursor populations, a range of transcription factors involved in 
eosinophilopoiesis  appears  to  be  conserved  across  the  two  species.  In 
particular,  a  highly  coordinated  expression  of  several  transcription  factors, 
including  PU.1  (93 96),  CCAAT  enhancer binding  protein a  (C/EBP a  and 
C/EBP b) (95, 97 98) and the lineage instructing GATA 1 (95, 99 101) allows 
for  the  commitment  to  eosinophil  lineage  and  terminal  eosinophil 
differentiation. 
Another GATA 1 closely related transcription regulator, called friend of GATA 1 
(FOG 1) acts as GATA 1 antagonist and has to be downregulated to allow for 
the  eosinophil  lineage  commitment  (102).  Decidedly,  GATA 1  transcription   43 
factor plays a central role for eosinophil generation (103). This suggestion was 
confirmed by a study on the targeted deletion of high affinity GATA binding site 
(so called  double  GATA  site)  which  is  commonly  spread  across  many 
eosinophil related  genes,  including  major  basic  protein  (MBP),  CCR3,  IL 5Ra 
chain and in the GATA 1 gene promoter itself. The deletion of a double GATA 
site  abrogates  eosinophil  lineage  development  in vivo  in  so called  ∆dblGATA 
mice  (95,  101,  103).  Deficiency  for  C/EBP a  exerts  a  more  broad  effect 
preventing  the  differentiation  of  any  granulocyte  sub populations,  including 
eosinophils  (104).  The  disruption  of  PU.1  gene  also  can  significantly  impair 
terminal  differentiation  of  eosinophil.  In  eosinophil  lineage  committed  cells, 
PU.1 appears to combine its effect with GATA 1 to produce the characteristics 
typical of eosinophil leukocyte, whereas in most other cells the two transcription 
factors mutually antagonize one another, where PU.1 represents the myeloid 
and GATA 1 the erythroid differentiation choice (95). Interestingly, the level of 
GATA 1 transcription required for eosinophil lineage commitment has to be just 
right, and can be characterized as low to moderate, with no FOG 1 expressed. 
There  are  data  suggesting  that  moderate  GATA 1  expression  is  both 
indispensable and sufficient for driving eosinophil development (105). Beyond 
the  commitment  of  common  myeloid  progenitors  to  eosinophil  lineage  a 
different member of C/EBP family, more specifically, certain isoforms of C/EBP e 
transcription  factor  are  required  for  terminal  differentiation  and  functional 
maturation  of  human  eosinophils  while  other  forms  counteract  terminal 
differentiation (106). Moreover, mice deficient for this transcription factor lack 
both  mature eosinophils  and  neutrophils  (104,  107).  Finally,  loss  of  C/EBP e 
function  caused  by  a  known  human  SNP  leads  to  the  failure  of  secondary   44 
granule proteins expression (both in the eosinophil and neutrophil lineages) in 
patients with so called specific granule deficiency (SGD) (108). 
In  2008,  another  transcription  factor,  Icsbp  (interferon  consensus  sequence 
binding  protein;  also  known  as  IFN  response  factor 8)  was  reported  to  be 
essential  for  eosinophil  development  as  Icsbp  deficient  mice  have  a  lower 
number of eosinophil progenitor cells, compared to wild type as well as exhibit 
lower  eosinophil  counts  in  a  steady state  and  fail  to  produce  eosinophilia  in 
response  to  nematode  Nippostrongylus  brasiliensis,  despite  high  amounts  of 
IL 5  expressed  upon  infection  (109).  Authors  suggest  that  Icsbp  controls 
GATA 1 expression. 
This precisely balanced interplay between GATA 1 FOG 1, PU.1, C/EBPa, Icsbp 
and  C/EBP e  transcription  factors,  both  in  terms  of  their  relative  expression 
levels and timing, is essential for effective eosinophil generation. The end result 
is  the  development  of  a  unique  eosinophil  lineage affiliated  pattern  of  gene 
expression where genes such as eosinophil peroxidase (EPO), and major basic 
protein  (MBP)  are  exclusive  to  eosinophil  lineage  while  several  other 
granulocyte associated genes are permanently shut down in eosinophils, such 
as  basophil specific  histidine  decarboxylase  (HDC),  neutrophil specific 
myeloperoxidase  (MPO)  and  mast  cell specific  proteinases.  This  unique  gene 
pattern was used to molecularly engineer a mouse strain specifically devoid of 
eosinophil, so called PHIL mice, by linking the expression of bacteria derived 
toxin with the expression of EPO, thus preventing eosinophils from undergoing 
maturation process (110).   45 
1.2.2.  Eosinophil recruitment and trafficking 
Terminal  stages  of  eosinophil  maturation  seem  to  be  inherently  linked  to 
eosinophil  exit  from  the  bone  marrow  into  the  circulation.  This  is  largely 
dependent on the combinatorial action of cytokines, such as IL 5 and other Th2 
cytokines,  IL 4  and  IL 13,  chemokines,  in  particular  of  eotaxin  family  and 
RANTES (111), and several adhesion molecules such as a4, b 1, b 2 and b 7 
integrins  (112)  and  surface  markers,  such  as  CCR3  (113 115).  Again,  IL 5 
appears to be the central cytokine in eosinophil recruitment and trafficking as 
IL 5  deficient  mice  exhibit  markedly  reduced  numbers  of  both  circulating 
eosinophils and bone  marrow resident eosinophil precursors (116). This was 
further  confirmed  in  the  human  system  in  trials  of  anti IL 5  therapy 
(mepolizumab)  when  decreased  eosinophil  counts  were  reported  in  the 
bronchial  mucosa  of  atopic  asthmatics  (117 118).  Along  with  IL 5  also  the 
eotaxins are well recognized as the most lineage specific factors that control 
eosinophil  mobilization,  trafficking  and  survival  in  the  tissue,  e.g.  lung 
infiltration following antigen exposure (119 120). Their chemotactic effects are 
mediated  by  the  G  protein coupled  membrane  bound  receptor,  CCR3  (121 
123). It is noteworthy that several CCR3 ligands, particularly eotaxin 1 (CCL11) 
and  eotaxin 2  (CCL24)  cooperate  with  IL 5  in  orchestrating  eosinophil 
trafficking  and  tissue  accumulation  by  expanding  the  CCR3
+  pool  and/or 
priming  eosinophils  to  respond  to  eotaxins  (111).  Interestingly,  while  CCR3 
signaling usually results in the activation and prolonged survival of eosinophil, 
more recent studies reported that CCR3 can also mediate strong negative signal 
able  to  arrest  key  eosinophil  responses,  particularly  when  Mig  (CXCL9) 
chemokine  acts  as  a  ligand,  through  a  Rac2  dependent  pathway  (124).  In   46 
humans, eosinophil trafficking is also regulated by eotaxin 3 (CCL26), which is 
only distantly related to the other two mentioned previously and it does not 
have a functional counterpart in mouse (125).  
Eotaxins are able to synergize with IL 5 to induce IL 13 production in the lung. 
In turn, IL 13 can synergize with IL 4 to potently induce eotaxins in the lung 
tissue  through the  STAT6 dependent mechanism which partially  explains the 
causative relationship between Th2 responses and associated lung eosinophilia 
(111). This finding was further confirmed in IL 4 reporter mice infected with the 
migrating intestinal helminth, Nippostrongylus brasiliensis where eosinophil and 
Th2  cell  recruitment  into  the  lung  was  shown  to  be  dependent  on  STAT6 
expression  by  bone  marrow derived  tissue  resident  cells  (that  were 
characterized as non T, non B cells) (126). 
Importantly,  in  the  course  of  antigen induced  airway  inflammation,  Th2 
cell derived IL 13 facilitates eosinophil trafficking from peripheral blood into the 
lungs  by  controlling  the  expression  of  eotaxin  and  eotaxin 2.  Each  of  those 
chemokines  is  responsible  for  eosinophil  trafficking  into  a  different  lung 
compartment.  While  eotaxin  expression  appears  to  be  induced  in  lung 
pneumocytes,  the  expression  of  eotaxin 2  occurs  in  alveolar  macrophages 
(luminal  inflammatory  cells).  Consistently,  mice  deficient  for  eotaxin 2  show 
markedly reduced BAL eosinophilia upon IL 13 administration (127). 
An interesting example of a surface marker involved in eosinophil trafficking is a 
sialic acid binding immunoglobulin like lectin, Siglec F (and its human functional 
paralog Siglec 8). This sialoadhesin is markedly upregulated on blood and bone   47 
marrow eosinophils in response to the induction of allergic lung inflammation 
despite its well established role as part of a negative eosinophil regulation both 
in vitro and in vivo (128 129). 
1.2.3.  The effector functions of eosinophils 
Current knowledge about this highly specialized yet multifunctional leukocyte is 
still expanding. At homeostatic baseline, eosinophils are commonly found in the 
bone  marrow  where  they  constitute  a  small  but  stable  sub population  that 
consists of both mature eosinophil cells and also eosinophil lineage precursors 
at  various  stages  of  development.  As  mentioned  in  previous  section,  rapid 
expansion of this population upon diverse stimuli, the most specific of which is 
IL 5,  serves  as  a  major,  and  probably  the  only,  source  of  terminally 
differentiated eosinophil leukocytes that are subsequently recruited to the sites 
of inflammation mobilized by a range of chemokines, such as eotaxin, together 
with  several  adhesion  molecules.  Outside  the  bone  marrow,  eosinophils 
normally constitute 1 5% of blood nucleated cells and resident populations of 
tissue  eosinophils  are  commonly  found  in  the  gastrointestinal  tract  (GI), 
particularly in the transitional area between the small intestine and the colon 
(cecum).  These  are  also  present  in  thymus,  spleen,  lymph  nodes  and 
endometrial  lining  of  the  uterus  (endometrial  stroma)  (130 131)  and  are 
required  for  postnatal  mammary  gland  development  (132).  Although  it  is  a 
long known phenomenon that eosinophils can be recruited in response to tissue 
damage and tissue repair, the details about the nature of their involvement in 
those processes are incomplete and poorly understood (133 136). In addition, 
eosinophil major basic protein (MBP) have been implicated as a pro angiogenic   48 
factor, based on evidence from in vitro and in vivo studies which may be of 
particular relevance to tissue repair and remodelling that contributes to asthma 
pathology (137). 
Eosinophils  are  widely  recognized  as  the  major  effector  cells  in  type 2 
inflammatory diseases, including helminthic infection, asthma, and allergy (130, 
138). The important role of eosinophils in the immunopathogenesis of asthma 
was  shown  in  studies  using  eosinophil deficient  mice  that  develop  markedly 
attenuated responses in experimental airway inflammation models (110, 139).  
Two distinct mouse strains devoid of eosinophils have been generated using 
different molecular approaches. In one case, mice harbor targeted mutations in 
the gene encoding a transcription factor GATA 1 ( dblGATA mice) (139 140). 
In so called PHIL mice, on the other hand, eosinophil ablation was achieved 
through the lineage specific expression of the diphtheria toxin A chain, under 
control  of  the  eosinophil  peroxidase  promoter  (110).  The  latter  strain  (on  a 
C57BL/6  background),  is  fully  protected  from  airway  hyperresponsiveness 
(AHR)  and  exhibits  diminished  airway  mucous  metaplasia  as  well  as  Th2 
cytokine  levels  in  OVA induced  airway  inflammation.  Similar  phenotype 
characterized  by  reduced  AHR  as  well  as  diminished  IL 4,  IL 5  and  IL 13 
production  was  reported  in   dblGATA  mice  if  bred  on  C57BL/6  (140).  In 
contrast,  dblGATA mice on the BALB/c background develop AHR and mucus 
production comparable to WT mice in OVA induced airway inflammation model 
(139). However, they showed reduced lung remodeling (which was not tested 
in PHIL mice). The above studies suggest that on the C57BL/6 but not BALB/c 
background,  eosinophils  are  essential  to  the  development  of  allergic  airway   49 
inflammation.  These  differences  in  phenotype  between  the  two   dblGATA 
mouse strains may also provide an insight into why there is no direct correlation 
between lung eosinophilia and the severity of asthma in a subset of asthma 
patients treated with IL 5 blocking monoclonal antibody (141). 
In asthma, eosinophils mediate the inflammatory process through the release of 
cytotoxic  granules  and  lipid  mediators  that  induce  tissue  damage  and  affect 
nerves, which, in turn, causes bronchoconstriction (129 130, 138, 142 143). In 
addition,  eosinophils  show  numerous  immune  regulatory  functions,  including 
the  production  of  a  range  of  cytokines  and  chemokines  that  leads  to  the 
exacerbation of inflammation, mucus secretion, and lung remodelling (129 130, 
138,  143).  Recently,  it  was  demonstrated  that  bone  marrow  eosinophils  are 
essential for the survival of plasma cells through the release of the proliferation 
inducing ligand APRIL and IL 6; eosinophil deficient mice exhibit much lower 
numbers of plasma cells both in the resting BM and after immunization (144). 
Thus, eosinophils support humoral immune response thereby helping to ensure 
long term protection against pathogens. 
Eosinophils are also  one of the primary sources of IL 4 during  the initiation 
phase  of  type 2  immune  responses  (126),  and  they  can  recruit  T cells  by 
releasing  TARC  (CCL17)  locally  into  the  lungs  during  asthma  development 
(145). There is also  growing evidence that eosinophils can serve as antigen 
presenting  cells  (146).  A  summary  of  the  multiple  effector  functions  of 
eosinophils in the airways is shown in Figure 1.4.   50 
1.3.  Macrophage 
1.3.1.  Macrophage subpopulations 
Macrophages  are  specialized  hematopoietic  cells  distributed  throughout 
different tissues of a body where they play central role in homeostasis, tissue 
remodelling  and  host  defence.  One  of  the  key  functional  characteristics  of 
macrophages is that, depending on micro environmental factors, they can be 
specifically polarized so they are able to deal with a particular stimulus in a 
most  adequate  manner  (147).  In  addition,  the  heterogeneity  of  circulating 
monocytes  may  pre define  their  polarization  fate  once  they  arrive  at  tissue 
(148 149). 
Polarized  macrophages  have  been  broadly  classified  as  either  M1  or  M2 
macrophages. (see Figure 1.5.). Classically activated M1 macrophages were 
described as being responsive to type 1 inflammatory cytokines and microbial 
products,  and  by  producing  high  levels  of  IL 12,  whereas  M2 macrophages 
have  been  generally  characterized  by  their  low  expression  of  IL 12.  M2 
macrophages can be further divided into three groups, based on the activation 
factors they are responsive to: M2a (alternatively activated macrophages, AAM) 
are induced by IL 4 or IL 13; M2b can be induced by immune complexes and 
agonists of TLRs or IL 1 receptors; M2c (immunosupressive) are induced by 
IL 10 or TGF b or glucocorticoids (150 151). Furthermore, macrophage subsets 
differ in their receptor expression, cytokine and chemokine expression and in 
their  effector  functions  (152).  M1  macrophages  are  well  defined  as  potent 
effector cells involved in responses against microorganisms and tumor cells as   51 
well  as  in  pathologic  type 1  inflammation.  Their  inflammatory  repertoire  is 
characterized  by  the  secretion  of  IL 12,  TNF a,  IL 1b,  IL 23,  IL 6,  IP 10, 
RANTES and the high expression of iNOS. M1 macrophages express many TLRs, 
including  TLR2,  and  opsonic  receptors  such  as  CD16.  In  contrast,  M2 
macrophages  ameliorate  type 1  inflammatory  responses  and  adaptive 
immunity,  and  regulate  type 2  immune  responses,  angiogenesis  as  well  as 
tissue remodeling. Various subsets of M2 macrophages exhibit these general 
properties.  Promotion  of type 2  response  in  helminthic  infection,  allergy  and 
asthma  are  typical  of  AAM,  whereas  suppression  of  both  type 1 and 2 
inflammation is a predominant feature of M2c cells. The M2 macrophage profile 
and the AAM in particular can be characterized by abundant expression of non 
opsonic  receptors  such  as  the  mannose  receptor  (MR;  CD206)  and  CD163. 
Moreover,  Arginase I  is  upregulated  in  AAM  and  M2c  macrophages,  which 
results  in  generation  of  polyamines  and  proline  by  these  cells,  thereby 
contributing to wound healing and pathological fibrosis (150 153). 
A growing interest in the role and function of AAM in parasitic infection and 
asthma led to the identification of more specific markers for AAM.  The most 
relevant signature markers besides Arginase I, MR and IL 4Ra are chitinase like 
lectin Ym1, resistin like secreted protein FIZZ1 and acidic mammalian chitinase 
(AMCase)  (154).  Furthermore,  a  distinct  chemokine  profile,  including  TARC 
(CCL17), MDC (CCL22) and Eotaxin 2 (CCL24), has been associated with AAM 
activation (152).   52 
1.3.2.  The role of alveolar macrophages in the regulation of 
immune response 
The function of the lungs is to allow the uptake of oxygen and the excretion of 
carbon  dioxide.  With  its  large  surface  area,  the  lungs  are  exposed  to  many 
pathogens as well as harmless antigens. Since oedema and inflammation can 
lead to the thickening of alveolar walls and compromise gas exchange, immune 
defence of this barrier has to be tightly controlled (155). A cellular component 
of the immune response in the lungs consists mainly of alveolar macrophages 
which adhere closely to alveolar epithelial cells. It has been shown that to avoid 
damage to alveoli, alveolar macrophages are generally kept in a quiescent state 
which  resembles  M2c  phenotype  (immunosuppressive)  (156).  By  producing 
cytokines  such  TGF b1  they  actively  suppress  the  induction  of  adaptive 
immunity to harmless antigens through their effects on alveolar and interstitial 
DCs and T cells (156 158). However, in the presence of ‘danger signal’ which 
either comes from a pathogen or damaged tissues, alveolar macrophages are 
believed to be responsible for the initiation of the inflammatory response (159 
162).   53 
1.4.  Aims of the project 
Numerous clinical studies and animal models revealed much of the complexity 
of the asthma and allergic diseases including a prominent role of adaptive arm 
of  immunity,  in  particular,  Th2  cells  but  also  cells  associated  with  innate 
immunity  such  as  eosinophils,  mast  cells,  and  macrophages.  All  those  cell 
populations were thought to be driven chiefly by cytokines and other mediators 
derived from allergen activated Th2 cells, in particular by IL 5, IL 4 and IL 13. 
Among those cytokines, IL 5 is widely recognized as one of the key factors that 
drive  asthma  pathogenesis  owing  to  its  known  activity  as  a  selective 
eosinophilopoietin and chemoattractant, thus required for eosinophil infiltration 
of the airways that eventually leads to profound histological changes including 
airway  hyperresponsiveness,  excessive  mucus  production  and  airway  tissue 
remodeling. Indeed, atopic patients often exhibit elevated levels of serum IL 5 
which was commonly associated with high eosinophil counts in the sputum and 
more frequent asthma exacerbation episodes. Furthermore, data obtained from 
mouse airway inflammation models suggested that disrupting the IL 5 signaling 
may  constitute  an  effective  therapeutic  approach  through  controlling  airway 
eosinophilia.  
However, clinical investigations revealed that the use of monoclonal anti IL 5 
antibody in asthma patients is not necessarily the best way to control eosinophil 
counts and/or eosinophil activation status in the airways (163 165). This may 
have been partially due to the reported a decrease in the IL 5Ra expression in 
the airways (166) in conjunction with a possible compensative increase in blood   54 
IL 5 (suggestive of ‘endogenous’ IL 5 auto regulatory pathway) (167), which 
could  not  be  counteracted  with  anti IL 5  administration.  Thus,  the  strategy 
aimed at preventing pathological changes in the atopic airways by controlling 
eosinophil population trough disrupting the signaling of IL 5 has been deemed 
insufficient. 
Recent studies, including those carried out in our laboratory suggest that there 
are,  in  fact,  other  factors  that  may  contribute  to  asthma  pathology.  For 
instance,  a  recently  discovered  interleukin 33  was  found  to  be  markedly 
elevated in lung epithelial cells of asthma patients compared to healthy donors 
(Figure 1.1.),  which  strongly  suggested  that  it  may  play  a  role  in  asthma 
pathogenesis through interfering with a local microenvironment of the airways. 
Indeed, we further demonstrated that IL 33 can profoundly alter the activation 
status  of  alveolar  macrophages  which,  in turn,  contributes  to  airway 
inflammation  (26).  Furthermore,  IL 33  has  been  shown  to  induce  IL 5  and 
IL 13 in CD4
+ cells (43) and serves as a T cell chemoatractant (168) thereby 
contributing to antigen driven airway inflammation. 
The main aims of this thesis therefore, were to further characterize the role of 
IL 33 in airway inflammation, by (I) investigating the mechanism in which this 
cytokine drives the differentiation of alveolar macrophages toward alternatively 
activated  (M2)  macrophages  and  (II)  how  this  affects  airway  cellular 
composition.  Furthermore,  since  eosinophilia  seems  to  be  a  prerequisite  for 
several  pathological  changes  in  asthmatic  lungs,  including  airway 
hyperresponsiveness  and  airway  tissue  fibrosis,  I  sought  to  investigate  (III) 
how  IL 33  contributes  to  eosinophil  biology  and  (IV)  how,  in  turn,   55 
IL 33 induced  eosinophil  mediators  affect  airways  homeostasis.  To  do  this  I 
employed a cell specific depletion method or an adoptive cell transfer method 
followed by the intranasal administration of IL 33 which mimics much of the 
allergic airway inflammation characteristics (4, 26, 43, 48).  
Chapter 3  of  this  thesis  provides  information  about  the  role  of  alveolar 
macrophages in the IL 33 induced airway inflammation. Chapter 4 investigates 
the effects of IL 33 on the population of eosinophil progenitor cells in the bone 
marrow and provides an insight onto the role of IL 33 in eosinophil trafficking 
through the regulation of the expression of CCR3, a key chemokine receptor 
involved in this process. Chapter 5 describes my studies of how IL 33 induces 
eosinophil activation and how some of the key eosinophil effector functions are 
regulated  by  IL 33  through  ST2  receptor  expressed  on  those  cells.  Finally, 
Chapter 6  provides  an  insight  into  the  role  of  IL 33 activated  eosinophils 
in vivo, as evaluated in IL 33 dependent airway inflammation model.   56 
 
 
 
 
 
 
 
 
 
Fig. 1.1.  Asthma  patients  express  more  IL 33  in  the  lung  epithelial  cells 
compared  to  healthy  subjects.  A C,  Frozen  sections  of  lung  biopsies  of 
asthmatic patients and healthy donors were stained with anti IL 33 antibody. 
Quantitative evalauation (A) and representative staining (B and C) are shown. 
Positive signal is violet. Data are means ± SEM (n = 10); *, p < 0.05, asthmatic 
versus controls. After Mariola Kurowska Stolarska et al. (26), PMID: 19841166.   57 
Fig. 1.2. IL 33 biology: target cells and cell specific effects 
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Fig. 1.3. Eosinophil development in the human and mouse system 
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Fig. 1.4. Eosinophil effector molecules and their biologic effects in the lungs 
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Fig. 1.5. Macrophage subpopulations and their effector functions 
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Chapter 2: 
Materials and methods   62 
2.1.  Animals 
Wild type (WT) BALB/c mice were purchased from Harlan Olac, (Bicester, UK). 
ST2  gene  knockout  (ST2
 / )  mice  on  the  BALB/c  background  that  harbor  a 
deletion  within  the  ST2  gene  spanning  across  exon  4  and  5  (169)  were 
obtained previously from Professor Andrew MacKenzie (Laboratory of Molecular 
Biology, MRC, University of Cambridge) and housed in the Biological Services 
facilities of the University of Glasgow in accordance with the United Kingdom 
Home Office regulations under the Animals (Scientific Procedures) Act 1986. All 
procedures  were  carried  out  under  Project  Licence  Number  60/3791, 
Procedure 3 and Procedure 5. 
Bone marrow from C57BL/6, IL 13
 /  and IL 5/IL 9/IL 13
 /  triple knockout mice 
on  the  C57BL/6  background  (170 171)  were  kindly  provided  by 
Professor Andrew McKenzie. 
2.2.  Recombinant IL-33 
Human  and  murine  recombinant  IL 33  used  in  all  in vivo  experiments  were 
produced  in  our  laboratory  according  to  published  protocols  (26,  168). 
Recombinant  IL 33  used  for  all  in vitro  experiments  was  purchased  from 
PeproTech (Rocky Hill, NY). Purity and biological activity of the two reagents 
was similar, as evaluated by its ability to induce IL 5 production from wild type 
but not ST2
 /  cells. 
In brief, the IL 33 generation protocol was as follows: mouse cDNA for IL 33 
was  cloned  from  IL 1 stimulated  fibroblasts,  and  the  cDNA  template  was   63 
transformed  into  Escherichia coli.  IL 33  protein  was  induced  by  IPTG  and 
purified by Ni NTA affinity chromatography. Traces of contaminating bacterial 
endotoxin were removed by passing the isolate through a polymyxin B column. 
Typically, the purity of IL 33 was more than 95% and endotoxin levels were 
less than 0.01 EU/ g of protein as evaluated by the Limulus Amebocyte Lysate 
QCL 1000 pyrogen test (Bio Whittaker, Bio Whittaker). 
2.3.  Reagents and buffers 
All  reagents,  including  buffered  saline  solutions  were  sourced  from 
Sigma Aldrich (Poole, UK). Culture media were purchased from Invitrogen Ltd 
(Paisley, UK), unless specified otherwise.  
Full list of chemicals used throughout the project includes: Phosphate buffered 
saline (PBS; 8g NaCl, 1.16g Na2HPO4, 0.2g KCl, 0.2g KH2PO4 in 1 litre distilled 
water, pH 7.4); Complete medium (500 ml RPMI 1640, 50 ml inactivated FBS, 
5ml pen / strep, 5 ml L glutamine); BD ELISA Coating buffer (0.1M NaHCO3 pH 
8.4); ELISA Wash buffer (0.05% Tween 20 in PBS pH 7.4); BD ELISA assay 
buffer (10% FCS in PBS); R&D ELISA assay buffer (1% BSA in PBS); Biousource 
ELISA assay buffer (0.5% BSA and 0.1% Tween in PBS); Substrate solution 
(1.8mM o phenylenediamine (OPD), 0.4mM H2O2 in 0.1M PBS containing 0.1% 
Triton X 100,  pH  8.0);  4M sulfuric  acid;  Formalin acetone  buffer  (0.75 mM 
Na2HPO4, 7.5 mM KH2PO4, pH 7.4, 45% v/v acetone, 10% w/v formaldehyde); 
DAB/H2O2 phosphate buffer (0.60 mM Na2HPO4, 7 mM KH2PO4, pH 7.5, 2 mM 
3,’3’ diaminobenzidine tetrahydrochloride); 0.01% H2O2 (prepared afresh from   64 
30%  v/v  solution);  8 mM potassium  cyanide  (KCN);  Avertin  stock  (1:1  w/v 
solution of 2,2,2 tribromoethanol in tert amyl alcohol). 
2.4.  Cell isolation and enrichment 
2.4.1.  Purification of mouse haematopoietic precursor cells 
Mice were sacrificed using carbon dioxide inhalation and the femur and tibia 
were aseptically removed from both hind limbs and stored in complete medium 
at 4
OC until the bone marrow was extracted. Under sterile conditions, bones 
were cut open from both ends and the shaft was flushed with pre chilled sterile 
BPS  using  a  needle  and  a  syringe.  Single cell  suspension  was  achieved  by 
passing the cells through a sterile 70mm nylon mesh (Costar). Then, cells were 
washed in 50ml of RPMI 1640 medium, centrifuged at 300g for 10 min at 4
OC 
and resuspended in complete medium prior to counting in a haemocytometer. 
For  CD117 positive  (Lin
 CD117
+)  cell  enrichment,  murine  BM  cells  were 
separated using MACS Miltenyi magnetic cell sorter. The protocol recommended 
by the manufacturer was closely followed (MACS Miltenyi Biotec). In brief, BM 
cells were passed through 30µm nylon mesh (# 130 0141 407, Miltenyi Biotec) 
to  remove  the  clumps  and  obtain  a  single cell  suspension.  Next,  lineage–
committed  cells  were  depleted  using  the  Lineage  Cell  Depletion  Kit,  mouse 
(#130 090 858,  Miltenyi  Biotec).  Lineage positive  cells  that  express  antigens 
from  a  panel  of  so called  ‘lineage’  antigens  (CD5,  CD45R  (B220),  CD11b, 
Anti Gr 1 (Ly 6G/C) and Ter 119 antibodies) retained on a MACS column, while 
lineage negative cells were allowed to pass through the column (separation by 
negative selection). In the following step, lineage negative cells were enriched   65 
for  CD117  antigen  using  CD117  MicroBeads,  mouse  (#130 091 224, 
Miltenyi Biotec) by positive selection. 
2.4.2.  Purification of mouse eosinophils 
Mouse eosinophils were obtained from bone marrow or peritoneal wash of WT 
and ST2
 /   mice  that  have  been  injected  with  IL 5  (2mg/mouse, i.p.) or  with 
IL 33  (2mg/mouse, i.p.)  over  7 days.  Eosinophil  leukocytes  were  separated 
using a flow cytometry based cell sorter (Becton Dickinson, FACSAria One). In 
brief,  cells  were  gated  for  Siglec F
+  or  Siglec F
+  and  CCR3
high  or  Siglec F
+, 
CCR3
high and Gr 1
intermediate and sorted into medium containing GM CSF (1ng/ml) 
or IL 5 (2ng/ml), to maintain cell viability. The purity ranged from 96 to 98%. 
Details are provided in the sections below. 
2.4.3.  Purification of human eosinophils 
Human eosinophils were acquired from peripheral blood of healthy volunteers 
by density gradient centrifugation (Histopaque, density 1.077 g/ml). In brief, 
20ml  of  cell  suspension  were  carefully  laid  over  20ml  of  Histopaque 1077 
solution and in a 50 mL conical tube and centrifuged at 600×g for 30 minutes 
at 20
OC in a swinging bucket rotor without brake. This was followed by the lysis 
of erythrocytes from the bottom fraction in ammonium chloride erythrocyte lysis 
solution (0.8% NH4Cl, 10mM KHCO3 and 0.1mM EDTA) in a fully filled 50ml 
conical tube (10minutes, on ice) and centrifugation at 300×g for 8 minutes. 
Cells  were  then  washed  by  adding  50  ml  of  MACS Running Buffer  (Miltenyi 
Biotec),  spun  down  again,  re suspended  in  appropriate  volume  of  Running 
Buffer and counted. Next, eosinophils were magnetically separated from other   66 
granulocytes  using  Eosinophil  Isolation  Kit,  human  (# 130 092 010,  Miltenyi 
Biotec) based on a panel of antibodies consisting of CD2, CD14, CD16, CD19, 
CD56, CD123, and CD235a (glycophorin A) designed for the negative selection 
of human eosinophils. Instructions provided by the manufacturer were closely 
followed to achieve efficient separation. Actual purity of eosinophil population 
was  verified  by  differential  cell  staining  or  staining  for  eosinophil specific 
cyanide resistant peroxidase (EPO) activity of cytospin preparations. The purity 
ranged from 96 to 98%. 
2.5.  Cell cultures 
2.5.1.  Eosinophil development from whole bone marrow and 
CD117
+ precursors 
Whole  bone  marrow  (2x10
6/well/1ml)  or  purified  CD117
+  haemopoietic  cells 
(0.5x10
6/well/1ml,  purity  ≥95%)  from  BALB/c,  ST2
 / ,  IL 13
 /   and 
IL 5/IL 9/IL 13
 /   were  cultured  in  RPMI 1640  (supplemented  with
  10% FCS, 
2mM  L glutamine,  100U/ml
  penicillin,  100µg/ml  streptomycin,  0.05M 
2 mercaptoethanol) and IL 5 (10ng/ml) or IL 33 (2, 10, 50ng/ml) (all cytokines 
from Peprotech) ± anti IL 5 neutralizing antibody or isotype control (10mg/ml, 
eBioscience).  After  4 5  or  7 8  days  of  culture,  cells  were  stained  with 
PE conjugated  anti Siglec F  (early  eosinophil  differentiation  marker;  BD 
Bioscience), APC conjugated anti CCR3 (an eosinophil marker; R&D Systems), 
FITC conjugated  anti ST2L  (MD  Bioscience),  PerCP conjugated  anti Gr 1 
(a granulocyte  marker;  BD Bioscience),  PE conjugated  anti FceR1  (a  basophil 
marker,  BD  Bioscience),  or  with  the  appropriate  isotype  control  followed  by   67 
FACS analysis (Table 2.1.). To analyze the effect of IL 33 on CCR3 expression, 
cells from WT and ST2
 /  bone marrow culture driven with IL 5 (10ng/ml) were 
resuspended,  in  PBS/2% FCS  (50x10
6/ml)  and  20ml  of  PE conjugated  rat 
anti mouse Siglec F antibody per 50x10
6 cells were added. Cells were incubated 
for 30min on ice followed by two washing steps (10ml of PBS/2% FCS; 10min, 
300g). After the last washing step cells were resuspended in PBS (50x10
6/ml) 
and  then  equal  amount  of  Cell  Dissociation  Solution  (Sigma)  was  added  to 
prevent forming cell clumps. The cells were then sorted by FACS, based on high 
Siglec F expression into complete medium supplemented with IL 5 (2ng/ml) to 
prevent cell death. Purity of sorted cells was evaluated and was ≥98%. Cells 
were then stimulated with IL 33 (10ng/ml) in media containing small amount of 
IL 5 (2ng/ml). After 24h, the cells were stained with APC conjugated anti CCR3 
antibody (4ml/100ml) for 30 minutes followed by two washing steps (10ml of 
PBS/2% FCS; 10 minutes, 300g). Cytospins were prepared from some cultures 
and  stained  in  the  presence  of  potassium  cyanide  for  EPO  (specific  for 
eosinophils) or were differentially stained with eosin/hematoxylin. 
2.5.2.  Eosinophil cytokine responses and surface markers  
WT and ST2
 /  mice were injected with IL 5 (2mg) i.p. every second day for 
7 days. Twenty four hours after last injection cells were harvested from bone 
marrow. Cells were then resuspended in PBS/2% FCS (50x10
6/ml) and 20ml of 
PE conjugated rat anti mouse Siglec F antibody (0.2mg/ml; BD Bioscience) and 
40ml  APC conjugated  rat  anti mouse CCR3  (R&D Systems)  per  1ml  (50x10
6 
cells) were added. Cells were incubated for 30 minutes on ice followed by two 
washing steps (10ml of PBS/2% FCS; 10 minutes at 300g). After last washing   68 
step cells were resuspended in PBS (50x10
6/ml). Next, equal volume of Cell 
Dissociation Solution (Sigma) was added to prevent forming cell clumps. The 
cells were then sorted by FACS, based on high Siglec F and CCR3 expression 
into  complete  medium  containing  1ng/ml  of  GM CSF  or  2ng/ml  of  IL 5  to 
prevent  cell  death.  Purified  populations  of  eosinophils  (purity  ≥97%, 
0.5x10
6/well/ml)  were  cultured  in  IL 5 containing  control  medium  (2ng/ml), 
supplemented  with  GM CSF  (1,  10ng/ml)  or  IL 4  (10ng/ml)  or  IL 33  (10, 
50ng/ml)  or  a  combination  of  these  cytokines.  After  24  or  48h,  cells  were 
stained  with  FITC conjugated  anti ST2L  and  APC conjugated  anti CCR3 
followed by FACS analysis (see Table 2.1. for details). To assay cytokine and 
chemokine  production,  purified  eosinophils  were  incubated  in  medium  with 
GM CSF  (1ng/ml,  survival and  ST2L  inducing  factor;  control)  ± IL 33  (10, 
50ng/ml).  After  48h  culture  supernatants  were  collected.  Cell  viability  was 
evaluated by counting in trypan blue and was ≥94%. Levels of cytokine and 
chemokine  production  were  evaluated  after  72 hours  of  culture  by  20 plex 
Luminex (Biosource) or ELISA using paired antibodies against IL 13 , TGF b1, 
IL 4 and chemokines MIP 1a, Eotaxin 1, Eotaxin 2, TARC (see Table 2.2. for 
details).  
2.5.3.  Eosinophil degranulation 
Mature human and mouse eosinophils were cultured in the presence of GM CSF 
(1ng/ml) ± IL 33 (50ng/ml) as before. After 24h, cells were washed with fresh 
RPMI medium and seeded into a plate coated with anti human CD32 or anti 
mouse CD32/16 (0.3 or 1mg/ml) or mIgG1 or hIgG1 (1mg/ml). After 90 minutes 
culture supernatants were collected and EPO assay performed. The amount of   69 
EPO  in  the  degranulation  assay  was  calculated  as  the  percentage  of 
total EPO released from eosinophils that underwent 3 freeze thaw cycles. EPO 
colorimetric assay was performed on cell supernatants according to previously 
published  protocol (172).  In  brief, aliquots  of  sample  (50ml)  were  incubated 
with  equal  volume  (50ml)  of  substrate  solution  containing  1.8mM 
o phenylenediamine  (OPD)  and  0.4mM  H2O2  in  0.1M  phosphate  buffer 
containing  0.1%  Triton X 100  (pH  8.0)  for  30min  at  37°C  followed  by 
acidification with 4M sulfuric acid. Results are shown as the percentage of total 
EPO. Cell viability was evaluated by differential cell counts using trypan blue. 
In  some  cultures,  cells  pre incubated  with  GM CSF±IL 33  were  stained  with 
PE conjugated  anti CD32  or  PE conjugated  anti CD16  antibodies  followed  by 
FACS analysis (see details in Table 2.1.). 
 2.5.4.  Macrophage differentiation in vitro 
Bone marrow cells from WT or ST2
 /  were cultured in RPMI 1640 supplemented 
with  10% FCS,  2mM  L glutamine,  100units/ml  penicillin,  100µg/ml 
streptomycin,  0.05 M 2 mercaptoethanol  on  Petri  dishes  10x10
6  per  5ml  per 
dish in the presence of M CSF (10ng/ml). After 3 days, cells were fed with 5ml 
of fresh complete medium supplemented with M CSF (10ng/ml). On day 6 of 
culture, cells were evaluated by flow cytometry (FACS) for macrophage marker 
and cell preparations containing ≥96% of F4/80
+ macrophages were used for 
further experiments.   70 
2.5.5.  Co-culture of eosinophils and macrophages 
Specially designed culture plates with well inserts were used throughout the 
co culture experiment series (Transwell system, 12 well plate, Costar). Upper 
compartment contained murine wild type eosinophils of 3x10
6/0.5 ml per well. 
A small pore diameter (0.4µm), permeable membrane was designed to prohibit 
cell migration between the compartments  without restricting  the diffusion  of 
soluble mediators. Lower compartment contained 0.5x10
6/well/1.5ml of ST2
 /  
macrophages. Cells were incubated with IL 5 (10ng/ml) or IL 33 (10ng/ml) ± 
neutralizing  anti IL 13  antibodies  (R&D  Systems)  or  isotype  controls  (both 
10mg/ml)  for  72h.  The  expression  of  TLR2  (eBioscience,  clone 6C2)  and 
mannose receptor (MR) (Serotec) on macrophages was then analyzed by FACS 
(Table 2.1.). 
2.6.  Murine model of allergic asthma 
WT and ST2
 /  mice were given i.p. injections with 100mg of OVA (Sigma) in 2% 
alum (Aluminium Hydroxide Gel Adjuvant, Brenntag) and then challenged i.n. 
on days 8, 9 and 10 with 10mg of OVA or PBS as described previously (173). 
Mice were sacrificed 48 120 h after the last challenge. Bronchoalveolar lavage 
(BAL) fluid was collected and analyzed. 
Mice  were  terminally  anaesthetized  by  the  i.p.  injection  of  500 l  of  Avertin 
(2,2,2 Tribromoethanol, Sigma Aldrich, 20mg/ml working solution in PBS, filter 
sterilized through a 0.5 micron filter, Millipore) then killed by exsanguinations 
after anesthetized sufficiently (no toe pinch/righting reflex, typically after about 
5 minutes). Next, the trachea was exposed and a small incision made at the   71 
proximal end to allow cannulation with a 23G needle sheathed with polythene 
tubing (VWR International). Then, a volume of 0.8ml of PBS was instilled into 
the lungs for about 15 seconds and the fluid was aspirated. Subsequently, a 
second aliquot of 0.8ml of fresh PBS was instilled as in the previous step. The 
two aspirated aliquots were then pooled in a 1.5ml centrifuge tube and stored 
on ice until the next step was carried out. Live cell counts were performed in a 
haemocytometer using trypan blue. Cells were spun onto glass slides using a 
Shandon Cytospin 3 (Shandon Scientific Limited, Cheshire, UK) at 450 rpm for 8 
minutes.  Then,  slides  were  air  dried  and  cells  were  fixed  by  incubation  in 
methanol at room temperature over 10 minutes. Slides were then stained by 
the Romanovsky method using Rapi Diff II (BIOS Europe Limited, Lancashire, 
UK).  Coverslips  were  affixed  onto  the  air dried  slides  using  DPX  (BDH 
Laboratory Supplies, Poole, UK). 
In  addition,  BAL  cells  were  stained  with  PE conjugated  anti Siglec F  and 
APC conjugated  anti CCR3  and  FITC conjugated  anti ST2L  antibodies 
(Table 2.1.) or matching isotype control.   72 
2.7.  IL-33-induced airway inflammation 
IL 33 (2mg/mouse) or PBS was administered intranasally for 3 consecutive days. 
To evaluate the contribution of IL 13 to IL 33 induced inflammation, mice were 
given  neutralizing  antibodies  or  appropriate  isotype  controls  (20mg/mouse) 
together with IL 33. To evaluate the contribution of alveolar macrophages to 
IL 33 induced  airway  inflammation,  clodronate  or  control  liposomes 
(40ml/mouse) were administered i.n. 72 and 24 hours prior to three intranasal 
IL 33 inoculations over the next three consecutive days (one IL 33 inoculation 
daily;  see  Figure 2.1.  below).  Clodronate  compound  was  a  gift  of 
Roche Diagnostics GmbH,  Mannheim,  Germany.  All  mice  were  sacrificed  on 
day 6 and, bronchoalveolar lavage fluids were analyzed. Cells from BAL were 
counted
  using  a  hemocytometer  as  detailed  in  previous  section.  Cytospin 
preparations
  were  made  using  a  Cytospin 3  apparatus  and  stained  with 
Diff Quick
  (Triangle  Biomedical  Sciences)  in  a  rapid  Romanowsky  staining
 
method (see section 2.6. for details). Differential cell counts were carried out 
using standard
 morphological criteria.   73 
 
 
 
 
 
Figure  2.1.  Intranasal  instillation  of  clodronate  liposomes  into  alveolar 
compartment. The depleting effect typically lasts up to 7 days. Two weeks prior 
to the first clodronate injection and during the experiment mice were kept in 
filtered cages and given sterile food and water. The 3 dose 6 day protocol for 
intranasal IL 33 administration was designed and optimised on the basis of the 
previous dose response and time course experiments that had been carried out 
by  other  members  of  our  laboratory,  namely  Nick  Pitman,  Peter  Kewin  and 
Grace Murphy (unpublished data). These data indicated that the midpoint of 
eosinophil  response  occurs  three  days  after  the  last  intranasal  IL 33 
administration and it is moderate in magnitude, compared to a 7 day model, 
which was an advantage in terms of animal welfare and corresponded better to 
the features of clinical asthma. 
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Figure 2.2.  Intranasal  instillation  of  clodronate  liposomes  (adapted  from 
http://www.clodronateliposomes.org/,  by  Dr. Nico van Rooijen).  The  method 
allows  for  a  specific  depletion  of  alveolar  macrophages  without  affecting 
macrophage  populations  in  any  other  compartment.  Key:  cL = clodronate 
liposomes; TR = trachea 
TR 
alveolar space 
lung parenhyma 
cL   75 
2.8.  Adoptive transfer of eosinophils 
BALB/c  mice  (n=10)  were  injected  with  mIL 33  (2mg)  intraperitoneally  for 
7 days.  Twenty  four  hours  after  last  injection  cells  were  harvested  from 
peritoneal wash. Cells were then resuspended in PBS/2% FCS (50x10
6/ml) and 
20ml  of  PE conjugated  rat anti mouse  Siglec F  antibody  (0.2mg/ml;  BD 
Bioscience) and 40ml of APC conjugated rat anti mouse CCR3 (R&D Systems) 
per 1ml (50x10
6 cells) were added. Cells were incubated for 30 minutes on ice 
followed by two washing steps (10ml of PBS/2% FCS; 10 minutes, 300g). After 
last washing steps cells were resuspended in PBS (50x10
6/ml) and them equal 
amount of Cell Dissociation Solution (Sigma) was added to prevent forming cell 
clumps. The cells were then sorted by FACSA, based on high Siglec F and CCR3 
expression into complete medium containing 1ng/ml of GM CSF to prevent cell 
death. Purity of sorted cells was evaluated and was ≥98%. The cells were then 
incubated  2 days  with  GM CSF  (1ng/ml),  stained  with  CFSE  (2mM)  and 
administered  intranasally  to  ST2
 /   recipients  (10x10
6/mouse).  IL 33 
(2mg/mouse) or PBS were administered intranasally on day 1, 2, and 3. Control 
recipient  mice  received  PBS  instead  of  cells  followed  by  IL 33  or  PBS 
inoculations. All mice were sacrificed on
 day 4 and BAL fluids were analyzed as 
described previously (see section 2.6. for details). BAL cells were stained with 
FITC conjugated  anti F4/80  antibodies  and  PE conjugated  anti TLR2  and 
APC conjugated  anti MR  or  APC conjugated  anti CD4  or  isotype  controls 
(Table 2.1.).   76 
2.9.  Flow cytometry (FACS) 
Cells  from  each  sample  were  washed  with  FACS  Staining  Buffer  (2% FCS in 
PBS, 0.09M NaN3), resuspended in 100ml of FACS Staining buffer and incubated 
with  FcBlocker  (anti  mouse  CD32/16  2ml/tube,  BD  Pharmingen).  After 
10 minutes  specific  fluorochrome conjugated  anitibodies  or  isotype  controls 
were added for further 30 minute incubation, followed by two washing steps in 
staining buffer (1ml/tube). After washing, the cells were resuspended in 400µl 
of  staining  buffer  and  analyzed  by  flow  cytometry  (FACSCalibur).  To  enable 
dead  cell  exclusion,  2ml  of  7 Amino actinomycin D  (7 AAD,  Via probe,  BD 
Biosciences) was added to each FACS tube immediately before acquiring and 
analysis on FACSCalibur flow cytometer (BD Biosciences). All data analysis was 
carried  out  using  the  FlowJo  software  (Tree  Star  Inc.,  Oregon,  USA)  or 
CellQuest  (BD Biosciences).  Details  concerning  antibodies  used  for  FACS 
staining are summarized in Table 2.1.   77 
 
Antigen  Label  Isotype  Stock  Volume/100
ml 
Company 
mST2L 
hST2L 
FITC  rat IgG1 
mouse IgG1 
1mg/ml  2ml  MD Bioscience 
mCCR3  APC  rat IgG2a  25mg/ml  4ml  R&D Systems 
mSiglec 
F 
PE  rat IgG2a  0.2mg/ml  2ml  BD Biosciences 
mGr 1  PerCP  rat IgG2b  0.2mg/ml  2ml  BD Biosciences 
hCD69  APC  mouse IgG1  0.2mg/ml  5ml  BD Biosciences 
hCD32  PE  mouse IgG1  100 tests  2ml  BD Biosciences 
hCD16  PE  mouse IgG1  100 tests  2ml  BD Biosciences 
mFceR1  PE  Rat IgG  0.2mg/ml  2ml  BD Biosciences 
mF4/80  APC  rat IgG2b  0.2mg/ml  2ml  AbD Serotec 
mMR  Alexa64
7 
rat IgG2a  50mg/ml  10ml  AbD Serotec 
mCD11c  FITC  Hamster 
IgG1 
0.2mg/ml  2ml  BD Biosciences 
mTLR2  FITC  rat IgG2b  0.2mg/ml  2ml  eBioscience 
 
Table 2.1. Monoclonal antibodies used for flow cytometry.  
                Key: m = mouse; h = human   78 
2.10. Cytokine immunoassays 
Cytokine  and  chemokine  contents  in  culture  supernatants  was  assessed  by 
means  of  enzyme  linked  immunosorbent  assay  (ELISA)  kits,  ELISA  paired 
antibodies and multiplexed immunoassay. The latter will be described in a next 
paragraph while this section provides details about standard ELISA protocols. 
In regard to antibody pairs from BD Biosciences, all reagents and samples were 
applied at a volume of 50ml/well. Flat bottomed ELISA plates (Immulon 4 HBX, 
Thermo Labsystems, Franklin, USA) were coated with capture antibody in BD 
ELISA coating buffer (0.1M NaHCO3 pH 8.4) and incubated overnight at 4
OC. 
Plates were washed three times with ELISA wash buffer (0.05% Tween 20 in 
PBS pH 7.4) and incubated 1 hour at 37
OC with 300ml/well of assay buffer (1% 
BSA in PBS). Following the blocking step, plates were washed three times and 
samples and standards were added. A 7 point doubling dilution standard curve 
in duplicates was used. Assay buffer served as blank (also in duplicates) and for 
the  dilution  of  the  standards.  Samples  and  standards  were  incubated  for  2 
hours  at  room  temperature  after  which  plates  were  washed  five  times  and 
biotinylated detection antibody diluted in assay buffer was added to all wells 
and  incubated  for  2 hours  at  room  temperature.  Subsequently,  plates  were 
washed  three  times  and  Streptavidin HRP  conjugate  (Extravidin,  Sigma)  was 
added in 1:1000 dilution. After 30 minutes of incubation at room temperature 
plates were washed three times and 100ml/well of TMB substrate was added 
(KPL, Gaithersburg, USA). Plates were developed in the dark for a maximum of 
30 minutes. Some assays were terminated earlier if blue colour had become 
clearly visible. Optical density was measured using an MRX II microplate reader   79 
(Dynex Technologies, Worthing, UK) at 630nm wavelength. Sample values were 
calculated from the standard curves using Revelation software package (Dynex 
Technologies).  
Similar protocol was followed for R&D antibodies except for the different ELISA 
assay  buffer  that  was  used  (see  Table 2.2.).  Also,  the  supplied  Eotaxin 2 
detection antibody required dilution in the R&D ELISA assay buffer containing 
2% normal goat serum. The latter had to be heat inactivated and cooled down 
to room temperature prior to antibody dilution. 
All antibody pairs used are detailed in Table 2.2.    80 
 
Analyte 
Capture Ab 
(mg/ml) 
Detection Ab 
(mg/ml) 
Sensitivity 
(pg/ml) 
Company 
mIl 4  2  2  20 20x10
3  BD Biosciences 
mIL 5  4  4  10 10x10
3  BD Biosciences 
mIL 6  1  1  10 10x10
3  BD Biosciences 
mIFN g  1  1  40 40x10
3  BD Biosciences 
mIL 13  kit  kit  5 5x10
3  R&D Systems 
mMIP 1a  kit  kit  5 5x10
3  R&D Systems 
mEotaxin 1  0.8  0.4  5 0.5x10
3  R&D Systems 
mEotaxin 2  2  0.08  4 4x10
3  R&D Systems 
mTARC  2  0.2  5 1x10
3  R&D Systems 
mTGF b1  4  0.2  15 1.5x10
3  R&D Systems 
 
Table 2.2. Monoclonal antibody pairs used for ELISA. 
              Key: m = murine   81 
2.11.  Multiplexed immunoassay (Luminex) 
This type of an immunoassay utilizes specific antibodies for the cytokines and 
chemokines of choice that have been coated on the designated beads that had 
been  coded  with  a  characteristic  combination  of  fluorescent  dyes.  Such 
modification  to  classical  ELISA  allows  for  the  simultaneous  identification  of 
multiple ligands in a single reaction volume.  
All  culture  supernatants  were  collected  and  stored  at   20
OC  until  they  were 
assayed using LMC006 (Cytokine Mouse 20 Plex). Full list of cytokines present 
on the Luminex plate included IL 2, IL 4, IL 5, IL 10, IL 12, IL 13, IFN g, IL 1b, 
IL 6, IL 8, TNF a, VEGF, IL 17, FGF, IL 1a and chemokines: KC, MCP 1, MIG, 
MIP 1a  and  IP 10.  The  assay  was  used  according  to  the  manufacturer’s 
instructions.  All  reagents  and  solutions  required  were  purchased  from  the 
original kits. A 96 well Luminex filter plate was pre washed with Wash solution 
using vacuum apparatus. Next, 50ml of fluorescent bead mixture was added into 
each well and washed twice with Wash solution. Subsequently, the following 
reagents were added per well: 50ml of Incubation Buffer, 100ml of standard or 
50ml of Assay Diluent plus 50ml of sample. Mixtures of fluorescent beads with 
samples or standards were then  incubated at room temperature for 2 hours 
with  agitation  in  the  dark.  Subsequently,  the  wells  were  washed  twice  and 
100ml per well of biotinylated detection antibody was added and incubated for 1 
hour as previously. Then, the plate wells were washed twice and 100ml per well 
of Streptavidin HRP was added and incubated for another 30 minutes as before. 
Next,  the  wells  were  washed  three  times  before  resuspending  the  beads  in 
100ml  per  well of  Wash  solution.  The  fluorescence bound  to the  beads  was   82 
analysed using a Luminex 100Ô analyse (Luminex Corporation, Texas, USA). 
Data was then analysed by means of Luminex software (Luminex Corporation). 
 
2.12.   Staining for cyanide-resistant eosinophil peroxidase 
Cytospin  preparations  of  1 5x10
4  cells  were  prepared  using  a  Cytospin 3 
apparatus  (Shandon  Scientific  Limited,  Cheshire,  UK).  Slides  were  fixed  for 
0.5min in ice cold (4
OC) formalin acetone buffer (see section 2.3. for details). 
Next,  slides  were  washed  with  room  temperature  tap  water  and  air  dried. 
Subsequently,  cells  were  stained  for  eosinophil specific,  cyanide resistant 
peroxidase activity using a previously described method (174 175); the validity 
of  this  method  was  also  verified  in  human  cells  (176 177).  Briefly,  cytospin 
preparations  were  incubated  in  DAB/H2O2 containing  phosphate  buffer 
supplemented with low concentration of KCN for 10 minutes (KCN was used 
instead  of  NaCN  as  the  source  of  cyanide  ion).  Subsequently,  slides  were 
washed by shortly immersing in fresh tap water, then briefly under running tap 
water, and air dried. Finally, cells were counterstained with hematoxylin and 
cover slips were affixed onto the air dried slides using DPX (BDH Laboratory 
Supplies, Poole, UK). 
Precautions  were  taken  to  avoid  contact  with  the  poison,  and  a  cyanide 
antidote was also kept available. At the conclusion of these experiments, all 
cyanide containing  solutions  were  disposed  of  in  accordance  with  relevant 
safety regulations by technical staff.   83 
 
2.13.  Extraction of RNA 
Freshly  isolated  human  peripheral  blood  neutrophils  and  eosinophils  were 
washed twice with PBS, gently centrifuged, and PBS residues were completely 
removed by aspiration. Cells were lysed in RLT solution (Qiagen), and stored at 
 20
OC until they were processed. The RNA isolation was carried out using the 
RNeasy  Micro  Kit  (Qiagen)  according  to  the  protocol  provided  by  the 
manufacturer.  Unwanted  genomic  DNA  was  removed  by  carrying  out  an 
optional step with the RNAse free DNase set (Qiagen) as recommend in the 
original  manufacturer’s  protocol.  The  RNA  contents  and  its  quality  was 
measured  using  a  NanoDrop  2000c  instrument  (Thermo  Fisher  Scientific). 
Samples were then stored at  80
OC until processed. 
 
2.14.  Reverse transcription polymerase chain reaction 
(RT-PCR) 
RNA samples were thawed and kept on ice until used as template in a reverse 
transcription  using  Superscript II  Reverse Transcriptase  set  (Invitrogen) 
according to the manufacturer’s protocol. The reaction mixture comprised of 
300ng of RNA template, 1mg Oligo(dT) (500mg/ml), 1ml of dNTP mix (25mM 
each) and nuclease free water (Qiagen). A total volume was 12ml per reaction, 
placed  in  a  nuclease free  microcentrifuge tube  (ABgene,  Surrey,  UK).  The 
mixture was incubated in 65
OC for 5 minutes then rapidly cooled to 4
OC. Next,   84 
4ml  volume  of  5X  First Strand  Buffer,  2ml  of  0.1M  DTT  and  1ml  of  RNase 
inhibitor  (40 units/ml)  were  added  and  incubated  at  42
OC  for  two  minutes. 
Subsequently,  1ml  (200 units)  of  Superscript II RT  was  then  added  and 
incubated  at  42
OC  for  50  minutes.  The  reaction  was  then  terminated  by 
incubation  at  70
OC  for  15  minutes.  Tubes  containing  PCR  mixture  with  no 
Superscript II served as negative controls. cDNA was then stored at  80
OC.  
 
2.15.  ST2L- and sST2-specific cDNA amplification (PCR) 
AmpliTaq Gold  360 DNA Polymerase (Invitrogen) was  used  to  amplify cDNA 
transcripts  of  interest. The  original  manufacturer’s  protocol  was  followed.  In 
short, reaction mixture (total of 25ml) consisted of 12.4ml nuclease free water 
(Qiagen),  2.5ml  AmpliTaq  Gold  360  Buffer  (10x),  2ml  Magnesium  Chloride 
(25mM), 2ml dNTP mix (10 mM, 2.5mM each; final concentration 200mm each), 
2ml  forward  primer  (final  concentration  1.0mM),  2ml  reverse  primer  (final 
concentration 1.0mM), 0.1ml (1U), AmpliTag Gold 360 DNA Polymerase, and 2ml 
cDNA template. Each polymerase chain reaction was performed using standard 
cycle  conditions  suggested  by  the  polymerase  manufacturer  (holding, 
10min/95
OC for AmpliTaq Gold activation; cycling: 35x denature, 30sec/95
OC 
anneal,  30sec/58
OC,  extend,  30sec/72
OC;  final  extension,  7min/72
OC;  final 
hold/4
OC). Amplifications were carried out using a Veriti 96 well Thermal Cycler 
(Applied Biosystems). Samples were normalized by reference to a housekeeping 
gene,  b actin,  as  a  reporter  gene.  Primer  pairs  for  human  ST2L,  sST2  and 
b actin were validated and kindly provided by Mark Moore.   85 
The  amplified  templates  were  then  analyzed  on  a  2%  agarose  (Gibco)  gel 
containing  0.8mg/ml ethidium bromide (Sigma)  in 0.5 times TBE buffer. Gels 
were run on at 80V, powered by a constant power supply (Pharmacia). Gel was 
then visualised under ultra violet (UV). 
2.16.   Statistical analysis 
Analysis of variance (ANOVA) followed by Tukey’s test or Student’s t test was 
applied  to  the  data.  All  data  are  expressed  as  mean ± SEM.  p < 0.05  was 
considered statistically significant.   86 
 
 
 
 
 
 
 
Chapter 3: 
The role of alveolar macrophages in IL-33-induced airway 
inflammation   87 
3.1.  Alveolar macrophages are required for IL-33-induced 
airway inflammation 
It has been previously reported that IL 33 is abundantly expressed in the lungs 
of  asthma  patients.  Consistently,  IL 33  overexpression  or  administration  of 
exogenous IL 33 into the  lungs leads to the development of symptoms that 
resemble key asthma features, such as lung eosinophilia, type 2 cytokine and 
chemokine  production  as  well  as  the  activation  of  epithelial  cells  (48,  178). 
However, it is still unclear which cell type is responsible for an initiation of this 
response. Using deficient mice or depletion antibodies Kondo et al excluded the 
contribution of T and B cells, NK cells, basophils and mast cells.  
Alveolar macrophages are predominant immune effector cell type resident in 
the alveolar spaces of the airways and it is believed that they are responsible 
for the initiation of inflammatory responses. We previously showed that IL 33 
can target macrophages and is a potent amplifier of bone marrow derived and 
alveolar macrophage differentiation toward alternatively activated macrophage 
(AAM, M2) phenotype (26). Those cells are characterized by high expression of 
pro fibrotic arginase I and production of chemokines such as TARC (CCL17) and 
eotaxin 2 (CCL24) (26). Thus, I hypothesized that alveolar macrophages are 
the cell type that acts as the first line of response upon IL 33 release and, in 
turn,  modulates  subsequent  immunological  events.  Naïve  mice  were 
administered with IL 33 (2mg i.n.) or PBS for 3 consecutive days and the mice 
were  culled  on  day 6.  Mice  receiving  IL 33  showed  lung  inflammation 
manifested  by  an  increase  in  total  BAL  cell  count,  including  eosinophil, 
macrophage and neutrophil cell counts (Figure 3.1.). In order to investigate   88 
the contribution of alveolar macrophages to IL 33 induced airway inflammation, 
clodronate or control liposomes (40 ml/mouse) were administered intranasally 
72 and 24 h before three consecutive days of intranasal IL 33 inoculations as 
described by Thepen et al. (157). This route of liposome administration affects 
alveolar  but  not  lung  parenchyma  macrophage  (157)  (Figure 2.2.).  The 
intranasal administration of clodronate liposomes was able to deplete around 
80%  of  alveolar  macrophages  compared  to  the  control  group.  Interestingly, 
IL 33  induced  significantly  less  severe  eosinophilia  in  alveolar 
macrophage depleted mice compared to control mice (Fig. 3.2.) indicating that 
IL 33 driven AAM activation of alveolar macrophages is likely responsible for 
IL 33 induced airway eosinophilia. 
3.2.  IL-33-induced airway inflammation and alternatively 
activated macrophage polarization are IL-13 dependent 
In our previous studies in vitro we were able to demonstrate that IL 13/IL 4Ra 
signaling is essential for IL 33 driven AAM activation by inducing the expression 
of  ST2L  (26).  To  confirm  the  contribution  of  IL 13  to  IL 33 induced  airway 
inflammation and alveolar macrophage differentiation in vivo, mice were given 
IL 13 neutralizing antibodies or appropriate isotype control (20 mg/mouse) for 5 
consecutive days. IL 33 was administered over the first three days. All mice 
were sacrificed on
 day 6. Neutralization of IL 13 significantly decreased total cell 
and  eosinophil  counts  in  the  BAL  by  45  and  55%  respectively  (Fig. 3.3.). 
Importantly,  anti IL 13  neutralizing  antibodies  markedly  decreased  the 
percentage  of  mannose  receptor positive  (MR
+)  alveolar  macrophages 
compared  to  the  control  group  (54 ± 8%  and  82 ± 2%  of  all  macrophage,   89 
respectively;  p < 0.05).  The  percentage  of  TLR2 positive  macrophages 
remained  unchanged  (Fig. 3.4.).  These  data  demonstrate  that  IL 13  is 
required,  at  least  partially,  for  IL 33 induced  airway  inflammation  and 
differentiation of alveolar macrophages toward AAM. 
Summary of Chapter 3 
Together, these data indicate that IL 33/ST2 signaling plays a significant role in 
the  polarization  of  alveolar  macrophages  toward  AAM  by  acting  via  IL 13 
dependent mechanism. Most importantly, alveolar macrophages are likely the 
first  line  of  response  to  IL 33  signal  and  as  such  are  major  factor  that 
contributes  to  the  initiation  and  maintenance  of  IL 33 induced  airway 
inflammation.   90 
 
 
 
 
 
 
 
 
 
Fig. 3.1.  IL 33  induces  airway  inflammation.  BALB/c  mice  were  treated  i.n. 
with IL 33 (2 mg/mouse) or PBS for 3 consecutive days (all groups n = 5). Mice 
were  sacrificed  on  day 6.  BAL  differential  cell  counts  are  shown.  Data  are 
means ± SEM. *, p < 0.05 PBS versus IL 33 treated mice. 
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Fig. 3.2.  A-B    Macrophage  depletion  results  in  diminished  eosinophilia  and 
lower total cell counts in BAL. Clodronate (n = 5) or control (n = 5) liposomes 
(both  40ml/mouse)  were  administered  i.n.  72  and  24h  before  i.n.  IL 33 
inoculation (3 consecutive days, 2mg/mouse/day). All mice were sacrificed on 
day 6  and  BAL  cells  were  analyzed.  BAL  differential  cell  counts  are  shown. 
A, Data  are  means ± SEM.  *,  p < 0.05,  clodronate  versus  control  liposomes. 
B, Representative data from FACS analysis of BAL cells is shown. 
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Fig. 3.3.  The  contribution  of  IL 13  to  IL 33 induced  airway  inflammation. 
BALB/c mice were treated i.n. with IL 33 (2mg/mouse) or PBS for 3 consecutive 
days. Some mice also received anti IL  13 neutralizing Abs (20mg/mouse) for 
5 consecutive  days.  The  control  group  received  isotype matched  rat  IgG  (all 
groups n = 5). Mice were sacrificed on day 6. BAL differential cell counts are 
shown.  Data  are  means ± SEM. 
#,  p < 0.05  IL 13  neutralizing  Abs  versus 
IgG treated mice. 
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Fig. 3.4. IL 33 induced differentiation of alveolar macrophages toward AAM is 
diminished by IL 13 neutralization. BALB/c mice were treated i.n. with IL 33 
(2mg/mouse)  or  PBS  for  3 consecutive  days.  Some  mice  also  received 
anti IL 13 neutralizing Abs (20mg/mouse) for 5 consecutive days. The control 
group received isotype matched rat IgG (all groups n = 5). Mice were sacrificed 
on day 6. Representative staining for MR and TLR2 of alveolar macrophages 
from anti IL 13 Abs and IgG treated mice is shown.   94 
 
 
 
 
 
 
 
Chapter 4: 
The role of IL-33 in eosinophil development   95 
4.1.  IL-33 promotes eosinophil development in bone marrow 
IL 33 can induce eosinophilia in mice (4, 48, 80). I showed in Chapter 3 that 
IL 33 activated alveolar macrophages are responsible for attracting eosinophils 
from the periphery into lungs. However, it is still not clear whether IL 33 can 
directly  affect  eosinophil  differentiation  and  activation.  In  this  chapter  I 
addressed the first part of this question by using several different methods and 
various eosinophil markers (89). Initially, I incubated whole bone marrow cells 
from  WT  or  ST2
 /   mice  with  IL 33  or  IL 5  for  5  or  8 days.  IL 5  and  IL 33 
induced eosinophil differentiation from bone marrow precursors of WT mice as 
determined  by  the  presence  of  eosinophil  peroxidase  (EPO,  eosinophil 
granule associated marker) (Fig. 4.1.). By contrast, IL 5 but not IL 33 induced 
eosinophil differentiation in ST2
 /  mice. There were no EPO
+ cells detected in 
the culture with medium alone in WT or ST2
 /  cultures. These data indicate that 
IL 33  can  induce  eosinophil  development  from  bone  marrow  cells  in  a 
ST2 dependent manner. 
 
4.2.  IL-33 directly drives eosinophils from haemopoietic 
precursor cells (Lin
-/CD117
+) 
To determine whether IL 33 can act directly on hematopoietic progenitor cells, 
CD117
+ (c kit
+) cells were purified from bone marrow of WT or ST2
 /  mice after 
depletion of committed or mature lineage positive cells and cultured as above. 
Freshly  isolated  BALB/c  Lin
 CD117
+  progenitors  expressed  ST2L  (Fig. 4.2.). 
The expression of IL 5Ra on these cells was below the detection level of flow   96 
cytometry  (Fig. 4.3.).  However,  the  expression  of  IL 5Ra  was  markedly 
increased in the cultures stimulated with IL 33 for 4 days (Fig. 4.4.). Eosinophil 
differentiation was analyzed by FACS using surface eosinophil specific marker, 
Siglec F. IL 5 could induce comparable numbers of Siglec F
+ cells that stained 
positively with eosin both in WT and ST2
 /  CD117
+ cell cultures (10 ± 2.5% 
and  9.2 ± 2.5%  respectively),  whereas  IL 33  could  induce 
Siglec F
+ eosin positive  eosinophils  only  in  WT  but  not in  ST2
 /   CD117
+ cell 
cultures  (10.5 ± 0.5%  and  1.2 ± 1%  respectively)  after  5  days  of  culture 
(Fig. 4.5., FACS; Fig. 4.7., quantitative diagram). The morphology of Siglec F
+ 
cells  from  IL 5   and  IL 33 driven  cultures  matched  typical  eosinophil  cell 
characteristics  with  pink orange  eosin stained  granules  in  the  cytoplasm  as 
shown in Fig. 4.6. Similar data were obtained for 8 day cultures; there were no 
live  cells,  including  Siglec F
+,  detected  in  8 day  cultures  with  medium  alone 
(data not included). In addition, IL 33 driven Siglec F
+ eosinophils expressed 
ST2L (Fig. 4.8.). 
These  results  therefore  indicate  that  IL 33  is  able  to  act  directly  on 
hematopoietic  progenitor  cells  and  stimulate  their  differentiation  to  mature 
eosinophils. 
4.3.  IL-33 driven eosinophil development is partially 
mediated by IL-5 
Given that IL 33 stimulates the production of cytokines associated with type 2 
immunity and eosinophil development (4, 43, 130), I examined the contribution 
of IL 5, IL 9 and IL 13 to the IL 33 induced development of eosinophils from   97 
bone  marrow  precursors.  Bone  marrow  cells  from  WT,  IL 13
 /   and 
IL 5/IL 9/IL 13
 /  triple knockout mice were cultured with IL 33 (5 or 20ng/ml) 
or  medium  alone  over  5 or 10 days  and  mature  eosinophil  population 
characterized  by  the  expression  of  CCR3  was  evaluated  by  FACS 
(CCR3
+GR 1
intermediate)  and  eosin positive  staining.  IL 33  could  induce 
comparable numbers of CCR3
+Gr 1
+ eosinophils from the precursors of IL 13
 /  
and  WT  mice  (9.5 ± 2%  and  9 ± 1.9%  respectively),  but  not  from  the 
precursor  cells  of  triple  knockout  mice  (2.5 ± 1.5%)  (Fig. 4.9.1-2.).  These 
results  suggest  that  IL 5  and/or  IL 9  but  not  IL 13  are  required  for  the 
IL 33 induced  eosinophil  differentiation  from  precursor  cells.  Since  IL 5  is 
known  as  a  major  eosinophil  differentiation  factor  (179),  I  cultured  CD117
+ 
hematopoietic progenitor cells with IL 33 in the presence of an IL 5 neutralizing 
antibody. The treatment with anti IL 5 monoclonal antibody markedly reduced 
the IL 33 induced differentiation of eosinophils (SiglecF
+CCR3
+) from CD117
+ 
cells (Fig. 4.10.). Consistent with this finding, WT CD117
+ cells stimulated with 
IL 33 produced substantial amounts of IL 5 compared to un stimulated cultures 
or IL 33 treated ST2
 /  CD117
+ cells (Fig. 4.11.). Furthermore, an increase in 
FceRI positive cells, likely basophils, were detected in cultures stimulated with 
IL 33 as reported previously by Schneider et al. (79), (Fig. 4.12.).  
Together, these data suggest that IL 33 driven eosinophils development from 
progenitor cells is ST2 and IL 5 but not IL 13 dependent. 
   98 
4.4.  IL-33/ST2 signaling is required for optimal expression 
of CCR3 on eosinophils 
CCR3 is a major chemokine receptor responsible for the mobilization of mature 
eosinophils from the bone marrow and their trafficking to sites of inflammation 
(130).  To  investigate  whether  IL 33  is  involved  in  the  regulation  of  CCR3 
expression during eosinophil differentiation, FACS sorted Siglec F
+ eosinophils 
from IL 5 driven bone marrow cultures (7 days) were checked for characteristic 
eosinophil morphology (Fig. 4.13.) and incubated with IL 5 (2ng/ml) ± IL 33 
for 24h and CCR3 expression determined by FACS. As expected, the majority of 
IL 5 driven  Siglec F
+  eosinophils  readily  expressed  CCR3  (Fig. 4.14., 
histogram),  however,  IL 33  was  able  to  further  increase  surface  density  of 
CCR3 on these eosinophils (Fig. 4.15., diagram). Next, I investigated whether 
there was any difference in the basal expression of CCR3 between IL 5 driven 
eosinophils from WT and ST2
 /  mice. Eosinophils from ST2
 /  mice expressed 
significantly less CCR3 than WT eosinophils (Fig. 4.16. and Fig. 4.17.). Thus, 
these results clearly indicate that the endogenous IL 33/ST2 signaling pathway 
enhances the expression of CCR3 on eosinophils. 
Summary of Chapter 4 
Together, this part of my study suggests that IL 33 is able to act locally in the 
bone  marrow  compartment  and  directly  stimulates  eosinophil  differentiation 
from hematopoietic progenitor cells in an IL 5 dependent manner.   99 
 
 
 
 
 
 
 
Fig. 4.1. IL 33 induces eosinophil differentiation from bone marrow cells. Bone 
marrow (2´10
6/ml) from WT or ST2
 /  mice were cultured with IL 5 (10ng/ml) 
or IL 33 (10ng/ml) for 5 days. The cell  number and dose of cytokines  used 
were optimized in preliminary experiments (data not shown). EPO staining of 
cultured bone marrow cells is shown (original magnification ´ 10; insets ´ 40). 
Data are representative of three independent experiments.   100 
 
 
 
 
 
 
 
 
Fig. 4.2. Freshly isolated Lin
 CD117
+ haematopoietic cells from WT mice readily 
express ST2L. Data are representative of three independent experiments. 
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Fig. 4.3. Freshly isolated Lin
 CD117
+ haematopoietic cells from WT mice do not 
express  IL 5Ra  at  the  level  detectable  by  FACS.  Data  are  representative  of 
three independent experiments.  
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Fig. 4.4. The expression of IL 5 receptor in CD117
+ cells can be upregulated 
by  IL 33  stimulation.  Representative  FACS  analysis  of  CD117
+  cultures  with 
IL 33  on  day 4  is  shown.  Data  are  representative  of  three  independent 
experiments. 
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Fig. 4.5.  IL 33  induces  eosinophil  differentiation  from  haematopoietic 
progenitor  cells  (FACS).  Lin
 CD117
+  haematopoietic  cells  (0.5´10
6/ml)  from 
BALB/c or ST2
 /  mice were cultured with IL 5 (10ng/ml) or IL 33 (10ng/ml) for 
5 days. Representative FACS analysis of CD117
+ cultures is shown. Data are 
representative of three independent experiments.   104 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6. Sorting eosinophils from Lin
 CD117
+ cells cultured in with IL 33. A D, 
gating used for sorting Siglec F
+ cells; A, Cells gated for big, granule containing 
cells in P1; B, cells from P1 stained with IgG PE before sorting (isotype control); 
C, cells from P1 stained with Siglec F PE before sorting where gate P2 was used 
to  sort  for  eosinophils;  D,  Siglec F
+  cells  in  gate  P2  after  sorting  (returned 
sample); E, Eosin stained cytoplasm and donut shaped nuclei of Siglec F sorted 
eosinophils obtained from cultures of WT CD117
+ cells with IL 5 or IL 33; a 
representative image of Siglec F
+ cells shown (original magnification ´ 40). 
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Fig. 4.7.  IL 33  induces  eosinophil  differentiation  from  haematopoietic 
progenitor cells. Quantitative evaluation of the eosinophil marker Siglec F on 
CD117
+ cells. CD117
+ haematopoietic cells (0.5´10
6/ml) from BALB/c or ST2
 /  
mice were cultured with IL 5 (10ng/ml) or IL 33 (10ng/ml) for 5 days. Data are 
means ± SEM  of  three  independent  experiments.  *p < 0.05,  IL 33   or 
IL 5 treated versus medium; #p < 0.05, WT versus ST2
 /  sample. 
Siglec F expressing cells (eosinophils)   106 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8. Siglec F
+ eosinophils that differentiate from Lin
 CD117
+ cells express 
ST2L.  Lin
 CD117
+  hematopoietic  cells  (0.5´10
6/ml)  from  BALB/c  mice  were 
cultured  with  IL 5  (10ng/ml)  or  IL 33  (10ng/ml)  for  5 days.  Representative 
FACS analysis of CD117
+ cultures is shown. Data are representative of three 
independent experiments.   107 
 
 
 
 
 
 
 
 
 
Fig. 4.9.1.  IL 33 induced eosinophil differentiation from bone marrow cells is 
markedly  inhibited  in  IL 5/IL 9/IL 13
 /   triple  knockout  mice  (5  days).  Bone 
marrow cells (2´10
6/ml) from WT (C57BL/6 background), IL 13
 /  (C57BL/6), or 
IL 5/IL 9/IL 13
 /  triple knockout mice (C57BL/6) were cultured with IL 33 (5 or 
20ng/ml) or medium alone for 5 days. Representative data on the expression of 
eosinophil  markers  CCR3
high  and  GR 1
intermediate  of  a  single  experiment  are 
shown. Technical duplicates were used to generate FACS data for each IL 33 
dose  used.  Eosin stained  CCR3
high  and  GR 1
intermediate sorted  cells  (gate  G1). 
Original magnification ´20; inset ´100. 
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Fig. 4.9.2.  IL 33 induced eosinophil differentiation from bone marrow cells is 
markedly  inhibited  in  IL 5/IL 9/IL 13
 /   triple  knockout  mice  (10  days).  Bone 
marrow cells (2´10
6/ml) from WT (C57BL/6 background), IL 13
 /  (C57BL/6), or 
IL 5/IL 9/IL 13
 /  triple knockout mice (C57BL/6) were cultured with IL 33 (5 or 
20ng/ml) or medium alone for 10 days. Representative data on the expression 
of  eosinophil  markers  CCR3
high  and  GR 1
intermediate  of  a  single  experiment  are 
shown. Technical duplicates were used to generate FACS data for each IL 33 
dose used. 
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Fig.  4.10.  IL 33–induced  eosinophil  differentiation  from  haematopoietic 
progenitor  cells  is  IL 5  dependent.  CD117
+  hematopoietic  cells  (0.5´10
6/ml) 
from  BALB/c  were  cultured  with  IL 33  (10ng/ml)  with  or  without 
IL 5 neutralizing  Ab  (or  isotype  control,  10mg/ml)  for  5 days.  Representative 
FACS data of mature eosinophil; Siglec F and CCR3 markers are shown. Data 
are representative of three independent experiments.   110 
 
 
 
 
 
 
 
 
 
Fig. 4.11.  IL 33  induces  IL 5  production  by  CD117
+  cells.  CD117
+ 
haematopoietic cells (0.5´10
6/ml) from WT or ST2
 /  (BALB/c background) mice 
were  cultured  with  IL 33  (10  or  50ng/ml)  for  5  days.  IL 5  levels  in  culture 
supernatants  were  determined  by  ELISA.  Data  are  means ± SEM  of  three 
independent  experiments,  *p < 0.05,  IL 33  versus  medium; 
#p < 0.05,  WT 
versus ST2
 / .   111 
 
 
 
 
 
 
 
Fig. 4.12. The effect of IL 33 on the development of basophils. A population of 
FceRI positive  cells  expands  in  cultures  of  WT  but  not  ST2
 /   cells  when 
stimulated with IL 33. CD117
+ cells were purified from bone marrow of WT and 
ST2
 /  mice after the depletion of committed and mature lineage positive cells 
and culture in the presence of IL 5 (10ng/ml) or IL 33 (10ng/ml) for 4 days. 
Cell phenotype was analysed by FACS using FITC anti CD 11c, PE anti FceRI 
antibodies  and  relevant  isotype  controls.  Data  from  a  single  experiment  are 
shown.  Similar  results  supporting  IL 33 driven  basophil  differentiation  were 
reported by Schneider et al. (79).   112 
 
 
 
 
 
 
 
Fig. 4.13.  The  purity  of  FACS sorted  eosinophils  was  confirmed  by  the 
presence  of  eosin  (pink  cytoplasm)  as  shown  in  this  microphotography.  WT 
bone marrow cells were cultured for 7 days with IL 5 (10ng/ml) followed by 
FACS sorting for Siglec F
+ cells. Original magnification ´20; inset ´100).   113 
 
 
 
 
 
 
 
 
Fig. 4.14.  IL 33  increases  eosinophil  CCR3  expression  (i).  FACS sorted 
Siglec F
+  eosinophils  from  IL 5 driven  (10ng/ml)  WT  bone  marrow  cultures 
(7 days  with  IL 5)  were  incubated  with  IL 5  (2ng/ml)  with  or  without  IL 33 
(10ng/ml) for 24h, followed by FACS analysis for CCR3 expression. Expression 
of  CCR3  by  FACS  is  shown.  Data  are  representative  of  three  independent 
experiments.  Control  =  IL 5  alone  (2ng/ml,  red  line);  IL 33  variant  = 
IL 5+IL 33 (2 and 10ng/ml respectively, blue line); Isotype = grey line. 
c
e
l
l
 
c
o
u
n
t
 
isotype 
control (IL 5 alone) 
IL 5+IL 33   114 
 
 
 
 
 
 
 
Fig. 4.15.  IL 33  increases  eosinophil  CCR3  expression  (ii).  FACS sorted 
Siglec F
+ eosinophils from IL 5 driven (10ng/ml) BALB/c bone marrow cultures 
(7 days  with  IL 5)  were  incubated  with  IL 5  (2ng/ml)  with  or  without  IL 33 
(10ng/ml)  for  24h, followed  by  FACS  analysis  of  CCR3  expression.  Data  are 
means ± SEM  (n = 3),*p < 0.05,  IL 5  versus  IL 5 + IL 33  (white  and  black, 
respectively). 
(IL 5)   115 
 
 
 
 
 
 
 
 
 
Fig. 4.16.  IL 33  increases  eosinophil  CCR3  expression  (iii).  FACS sorted 
Siglec F
+  eosinophils  from  IL 5 driven  (10ng/ml)  BALB/c  and  ST2
 /   bone 
marrow cultures were FACS stained and checked for CCR3 expression. Data are 
representative of three independent experiments.   116 
 
 
 
 
 
 
 
 
 
Fig. 4.17.  ST2
 /   eosinophils  expressed  reduced  levels  of  CCR3. 
FACS sorted  Siglec F
+  eosinophils  from  IL 5 driven  (10ng/ml)  WT  and  ST2
 /  
bone marrow cultures were checked for CCR3 expression. The percentage of 
CCR3
high cells is shown. Data are means ± SEM (n = 3), 
#p < 0.05, WT versus 
ST2
 /  of three independent experiments.   117 
 
 
 
 
 
 
 
Chapter 5: 
The role of IL-33 in modulation  
of effector functions of eosinophil   118 
5.1.  The regulation of ST2L expression on mature human 
and murine eosinophils 
Next,  I  looked  at  the  regulation  of  ST2  expression  on  mature  human  and 
murine eosinophils. Human peripheral blood (PB) eosinophils were isolated by 
negative selection (Miltenyi Biotec). The purity of eosinophils was evaluated by 
EPO and/or hematoxilin/eosin staining and showed ≥ 96% of cells positive for 
EPO and or eosin stained granules (Figure 5.1.). In contrast to PB neutrophils, 
eosinophil leukocytes easily expressed mRNA for ST2L and sST2 (Figure 5.2.). 
Subsequently, I evaluated surface expression of ST2L on human PB eosinophils 
isolated  from  6  volunteers.  PB  eosinophils  expressed  ST2L  protein  only 
marginally (less than 2% of cells) in majority of donors (4 out of 6). However, 
in  remaining  2 donors,  between  2  and  15%  eosinophils  expressed  ST2L 
(Figure 5.3., Figure 5.4.). Not surprisingly, the expression of ST2L on human 
eosinophils  could  be  potently  increased  by  the  ST2L  ligand  itself.  A  small 
increase  was  also  observed  in  the  medium  alone,  suggesting  that  ST2L 
expression may be regulated by certain component(s) of fetal calf serum (FCS). 
Interestingly,  IL 5  markedly  decreased  the  medium induced  ST2L  expression 
but  this  effect  could  be  still  overcome  by  the  stimulating  action  of  IL 33 
(Figure 5.3., Figure 5.4.). Similarly, murine mature eosinophils differentiated 
from bone marrow precursors in the presence of IL 5 and sorted by FACS for 
CCR3
high Siglec F
+ cells (> 98% pure, Figure 5.5.), did not express detectable 
amounts  of  ST2L  (Figure 5.6.).  To  investigate  whether  cytokines  that  are 
abundantly released during type 2 immune response can affect ST2L expression 
on  murine  eosinophils,  I  used  IL 5 driven  mature  eosinophils  from  WT  and 
ST2
 /   mice  and  incubated  those  cells  in  medium  containing  IL 5  (2ng/ml)   119 
supplemented with IL 33 or GM CSF or IL 4 (all 10ng/ml) or a combination of 
these  cytokines  for  48h.  Expression  of  ST2L  on  eosinophils  incubated  in 
medium with IL 5 alone was either below the sensitivity of FACS (Figure 5.6.) 
or  was  very  low  (Figure 4.8.).  However,  IL 33  (Figure 5.6.)  and  GM CSF 
(Figure 5.7.)  but  not  IL 4  (Figure 5.8.)  increased  ST2L  expression  on  WT 
eosinophils. An additive effect of GM CSF and IL 33 on ST2L expression was 
also observed in WT (Figure 5.7.) but not ST2
 /  mice (Figure 5.9.). Taken 
together,  these  results  demonstrate  that  mature  human  and  mouse  resting 
eosinophils  express  low  levels  of  ST2L  which  can  be  markedly  increased  by 
cytokines including IL 33 and GM CSF. 
 
5.2.  BAL eosinophils express ST2L during OVA-induced 
airway inflammation 
To  determine  whether  eosinophils  that  accumulate  in  the  lungs  during  the 
course of inflammation actually express IL 33R I evaluated ST2L expression on 
BAL eosinophils during the course of mouse OVA induced airway inflammation
 
(see Materials and Methods). BAL cells were isolated 48 120 h after the last 
antigen  challenge  and  the  expression  of  ST2L  on  CCR3
+  eosinophils  was 
evaluated by FACS. Based on the previous data (26, 43) I expected eosinophils 
(CCR3
+cells) to start accumulating in BAL as early as 24 h with a maximum 
120 h after the last challenge. BAL eosinophils expressed ST2L which was at its 
peak  48 h  after  the  last  challenge  (80%  of  eosinophils)  (Figure 5.10.) and 
gradually declined afterwards, down to nominal 2.5% on day 5. ST2L was not   120 
detected  in  control  eosinophils  from  ST2
 /   mice.  Thus,  the  kinetics  of  ST2L 
expression on eosinophils suggests that cytokines derived from OVA activated 
T cells are likely responsible for the increase of ST2L expression on eosinophils 
that accumulated in the lungs. 
Altogether, these data suggest that in the course of type 2 immune response 
eosinophils that are mobilized to the site of inflammation may acquire ST2L on 
the surface likely due to cytokines produced by antigen specific Th2 cells. 
 
5.3.  The role of IL-33 in eosinophil activation 
5.3.1.  IL-33 induces production of IL-13, IL-6, TGF-1b b b b and 
TARC 
Since IL 33 is abundantly expressed in the lungs of asthma patients and mice 
with OVA induced allergic inflammation (26 28, 43) and eosinophils at sites of 
inflammation express high levels of ST2L, (Figure 5.10.) I thus investigated 
the  contribution  of  IL 33  to  mature  eosinophil  function  in  more  detail. 
Eosinophils  are  a  source  of  pleiotropic  mediators,  including  cytokines, 
chemokines  and  tissue  damaging  granule  proteins  (130).  To  investigate 
whether IL 33 can modulate the production of these mediators, FACS sorted 
CCR3
+Siglec F
+ WT and ST2
 /  eosinophils were incubated in medium containing 
suboptimal amounts of GM CSF (1ng/ml) in the presence or absence of IL 33 
(10,  50ng/ml)  over  48h.  GM CSF  was  used  because  of  its  ability  to  act  as 
eosinophil  survival  factor;  it  can  also  upregulate  the  expression  of  ST2L.   121 
Evaluation  of  cytokine  contents  in  culture  supernatants  (ELISA  and  Luminex 
assay) revealed that IL 33 triggered the production of IL 13 (Figure 5.11.), 
IL 6 (Figure 5.12.) and strongly increased the production of TARC and TGF b 
(Figure 5.13, Figure 5.14. respectively) from WT but not ST2
 /  eosinophils in 
a dose dependent manner. IL 33 had little to no effect on the production of 
eotaxin,  eotaxin 2,  IL 4,  MCP 1,  IP 10  and  MIP 1a  (data  not  shown).  Other 
cytokines (IL 17, KC, MIG, FGF, IL 1a, IL 2, IL 5, IL 10, IL 12, IFN g, IL 1b, 
TNF a, VEGF) remained below the detection level of Luminex assay used (data 
not  shown). These data  indicate  that  IL 33 activated  eosinophils  may  be  an 
important source of IL 13, TARC, IL 6 and TGF b. 
 
5.3.2.  IL-33 exacerbates IgG-induced eosinophil 
degranulation 
It is well documented that eosinophils are source of tissue damaging granule 
proteins  (130,  138,  143,  180 181).  In  order  to  evaluate  the  contribution  of 
IL 33  to  the  process  of  eosinophil  degranulation,  mature  murine  eosinophils 
were cultured in the presence of GM CSF (1ng/ml) ± IL 33 (50ng/ml) as before. 
After 24 h, cells were washed with fresh RPMI medium and seeded into a plate 
coated with anti CD32/16 (0.3 or 1mg/ml) or mIgG1 (1mg/ml). After 90 minutes 
culture supernatants were collected and EPO assay performed. The amount of 
EPO in the degranulation assay was calculated as % of total EPO released from 
eosinophils  that  underwent  3 freeze thaw  cycles.  In  addition,  the  viability  of 
cells  was  evaluated  by  cell  counts  using  trypan  blue.  Both  plate bound 
anti CD32/16  and IgG triggered EPO release that was markedly increased in   122 
the IL 33 pre treated cells. However, trypan blue staining showed that, in both 
instances, an increase in the EPO release from IL 33 pre treated cells coincided 
with  a  higher  cell  death  rate  (Figure  5.15.,  Figure 5.16).  Thus,  the 
engagement  of  FcgII  receptor  on  mouse  eosinophils  in vitro  can  lead  to  an 
increase in eosinophil cell death. However, a close comparison of the proportion 
of the amount of EPO released with the proportion of viable cells that remained 
in  IL 33  pre treated  cultures  suggest  that  there  is  some  contribution  of  the 
degranulation derived  EPO.  Also,  I  performed  similar  experiments  in  human 
eosinophils purified from peripheral blood. Again, pre treatment of cells with 
hIL 33 increased EPO release by human eosinophils in anti CD32 Ab induced 
culture compared to non treated cells (Figure 5.17.). In contrast to the murine 
system, there was no difference between the two pre treatment conditions in 
anti CD32 Abs induced cell death. Thus it appears that in human eosinophils, 
the  contribution  of  apoptosis derived  EPO  release  is  modest  compared  to 
IL 33 potentiated degranulation. 
 
These  data  suggest  that  IL 33  is,  indeed  able  to  significantly  increase  the 
IgG triggered degranulation. In order to investigate the mechanism behind this 
process,  I  looked  at  the  expression  of  FcgRs  on  human  esoinophils.  FACS 
analysis  showed  that  the  pre treatment  of  human  eosinophils  with  IL 33 
increased  the  expression  of  FcgRII  receptor  (CD32)  but  not  FcgRIII  (CD16) 
(Figure 5.18.) likely rendering these cells more responsive to IgG binding and 
thus promoting degranulation.   123 
5.3.3.  IL-33-activated eosinophils polarize macrophages into 
AAM in an IL-13 dependent manner 
In the course of IL 33 triggered airway inflammation as well as in OVA induced 
asthma model alveolar and lung macrophages differentiate toward alternatively 
activated macrophages (M2, AAM) (26). This sub population of macrophages is 
largely responsible for the production of chemokines and fibrotic factors that in 
turn  perpetuate  lung  inflammation  and  fibrosis.  Given  the  abundance  of 
eosinophils  in  the  lungs  during  asthma  models  I asked  whether  IL 33 
stimulated eosinophils contribute to the activation of macrophages. To test this 
hypothesis I co cultured ST2
 /  BM derived macrophages with WT eosinophils 
in vitro in the presence or absence of IL 33 or IL 5. Eosinophils alone modestly 
elevated the percentage of MR
+ macrophages which was markedly increased by 
the presence of IL 33 but not IL 5 (Figure 5.19, Figure 5.20.). Furthermore, 
because IL 13 is a well defined M2 differentiation factor (150) and was found to 
be produced by eosinophils upon IL 33 stimulation (Figure 5.13.), I therefore 
investigated  whether  IL 13  produced  by  IL 33 activated  eosinophils  may  be 
responsible for the enhanced M2 (AAM) polarization. The presence of anti IL 13 
neutralizing  antibodies  partially  but  significantly  reduced  the  number  of 
MR
+ macrophages polarized by IL 33 activated eosinophils (Figure 5.21. and 
Figure 5.22.; assessed by ANOVA followed by Tukey’s test), indicating that 
IL 33   but  not  IL 5 activated  eosinophils  polarized  macrophage  to  the 
pro inflammatory AAM phenotype, at least in part, via IL 13.   124 
5.3.4.  IL-33 induces expression of activation marker CD69 on 
human peripheral blood eosinophils 
Also, I have preliminarily looked at the role of IL 33 in human PB eosinophils 
activation. I decided to evaluate the expression of CD69 as it was reported in 
the literature to be an early activation marker of human eosinophils (182). Its 
expression is elevated in response to several cytokines including IL 13 (183), 
GM CSF, IL 3, IL 5 in vitro and in vivo in BAL fluid of asthma patients (184). PB 
eosinophils were stimulated with hIL 5 (10ng/ml) or hIL 33 (10 and 50ng/ml) 
for 48h. Eosinophils cultured in medium alone expressed low levels of CD69 on 
the surface.  IL 5 strongly increased the expression of CD69.  Similarly, IL 33 
significantly  increased  the  expression  of  CD69,  primarily  on  ST2L  positive 
eosinophils.  These  data  therefore  indicate  that  indeed  IL 33  affects  the 
activation of human eosinophils (Figure 5.23., Figure 5.24). 
 
Summary of Chapter 5 
Together,  this  part  of  my  study  demonstrates  that  IL 33  enhances  multiple 
features  of  eosinophil  functions  including  cytokine/chemokine  production, 
interaction  with  other  cell  types  as  well  as  degranulation  and  therefore  an 
IL 33 rich environment in asthma and allergy may contribute to the pathogenic 
activities of eosinophils.   125 
 
 
 
 
 
 
 
 
 
Fig. 5.1.  The  evaluation  of  the  purity  of  human  eosinophils  isolated  from 
peripheral blood. Specific staining for eosinophil peroxidase (EPO) is shown in 
the upper panel; eosinophil EPO containing granules stain in red gold. Bottom 
panel  shows  a  classical  differential  eosin/hematoxylin  staining.  Left  panel, 
original magnification x 10; right panel, original magnification x20.   126 
 
 
 
 
 
 
 
Fig. 5.2. The expression of ST2L and sST2 mRNA can be detected in freshly 
isolated  eosinophils  but  not  neutrophils.  Specific  band  of  175 bp  (line 5) 
represents  PCR  product  of  ST2L.  Similarly,  the  band  of  149 bp  (line 12) 
represents  PCR product  of  sST2.  Lines  4,  11  contain  DNA  marker 
(1kb DNA ladder). Lines 1, 2, 8, 9 contain positive control (housekeeping gene, 
b actin). Negative control (lines 3, 10 contain no template). The representative 
pictures of two independent experiments are shown. Primer pairs were kindly 
provided by Mark Moore. 
   1    2    3    4     5    6    7    8   9   10  11   12  13  14 
E
o
s
i
n
o
p
h
i
l
s
N
e
u
t
r
o
p
h
i
l
s
C
t
r
(
-
)
1
k
b
 
l
a
d
d
e
r
E
o
s
i
n
o
p
h
i
l
s
N
e
u
t
r
o
p
h
i
l
s
C
t
r
(
-
)
E
o
s
i
n
o
p
h
i
l
s
N
e
u
t
r
o
p
h
i
l
s
C
t
r
(
-
)
1
k
b
 
l
a
d
d
e
r
E
o
s
i
n
o
p
h
i
l
s
N
e
u
t
r
o
p
h
i
l
s
C
t
r
(
-
)
ß-actin                                       ST2L
175bp
ß-actin                                       sST2
149bp
 
E
o
s
i
n
o
p
h
i
l
s
 
 
E
o
s
i
n
o
p
h
i
l
s
   127 
 
 
 
 
 
 
 
 
Fig. 5.3.  The  expression  of  ST2L  by  freshly  isolated  and  cultured  human 
eosinophils  (representative  data).  Peripheral  blood  human  eosinophils  were 
acquired  as  described  in  Materials  and  Methods  section  and  FACS  analyzed 
ex vivo or cultured in vitro over 2 days prior the evaluation of ST2L expression. 
FACS staining for ST2L was done with FITC conjugated monoclonal antibody 
(MD Bioscience). Dead cell were excluded by staining with ViaProbe. Medium 
alone  mildly  increased  ST2L  expression  while  IL 5  downregulated 
medium induced  ST2L.  IL 33  was  able  to  induce  ST2L  and  to  reverse  the 
IL 5 mediated  negative  regulatory  effect.  Representative  data  of  six 
independent experiments is shown. 
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Fig. 5.4. The percentage of ST2L expressing cells in fresh or cultured human 
eosinophils  (quantitative  data).  Peripheral  blood  human  eosinophils  were 
acquired as described in Materials and Methods section and FACS analyzed or 
cultured in vitro over 2 days prior ST2L expression evaluation. FACS staining for 
ST2L  was  done  with  FITC conjugated  monoclonal  antibody  (MD Bioscience). 
Data  are  means ± SEM  (n = 6);  #p < 0.05,  IL 5  versus  medium;  *p < 0.05, 
medium versus IL 33 or IL 5 + IL 33   
.  129 
 
 
 
 
 
 
 
Fig. 5.5. The purity of murine bone marrow derived eosinophils differentiated 
in vitro. After 48 hours of incubation in the presence of IL 5 bone marrow cells 
were sorted with FACS for CCR3
highSiglec F
+ cells (typically, the purity was > 
98%).   130 
 
 
 
 
 
 
 
 
Fig. 5.6. IL 33 but not IL 5 induces ST2L expression on murine eosinophils. 
Mature murine FACS sorted WT eosinophils (Siglec F
+CCR3
high) were cultured in 
medium with IL 5 (2ng/ml, control) or IL 5 (2ng/ml) + IL 33 (10ng/ml) over 2 
days. Data are representative of  two independent  experiments.  Both control 
medium  and  IL 33  variant  also  contain  the  same  concentration  of  IL 5 
(2ng/ml). 
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Fig. 5.7. IL 33 further increases the intensity of ST2L expression induced by 
GM CSF. Mature murine FACS sorted WT eosinophils (Siglec F
+CCR3
high) were 
cultured in medium with IL 5 (2ng/ml, control) or IL 5 + GM CSF (10ng/ml) or 
IL 5  + GM CSF (10ng/ml)  + IL 33 (10ng/ml)  over  2  days.  Data  are 
representative of two independent experiments. 
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Fig. 5.8. IL 4 does not induce ST2L expression on murine eosinophils. Mature 
FACS sorted  WT  eosinophils  (Siglec F
+CCR3
high)  were  cultured  in  medium 
+ IL 5 (2ng/ml, control) or IL 5 (2ng/ml) + IL 4 (10ng/ml) for 2 days. Data are 
representative of two independent experiments. 
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Fig. 5.9. ST2
 /  eosinophils do not express ST2L. Mature murine FACS sorted 
ST2
 /   eosinophils  (Siglec F
+CCR3
high)  were  cultured  in  medium  with  IL 5 
(2ng/ml,  control)  or  IL 5 + GM CSF  (10ng/ml)  or  IL 5  + GM CSF (10ng/ml) 
+ IL 33 (10ng/ml)  for  2  days.  Data  are  representative  of  two  independent 
experiments. 
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Fig. 5.10.  Airway  eosinophils  express  ST2L  during  OVA induced  airway 
inflammation model. WT and ST2
 /  mice were sensitized with OVA + alum and 
subsequently  challenged  with  OVA.  BAL  cells  were  collected  48,  72,  96  and 
120h after the last OVA challenge and stained with anti F4/80 Ab, anti CCR3 
and  anti ST2L  Abs.  At  48h  time  point,  up  to  80%  of  BAL  eosinophils 
(F4/80
-CCR3
+ cells) were ST2L
+. Pooled data from 10 mice at each time point 
shown.   135 
 
 
 
 
 
 
 
 
 
Fig. 5.11.  IL 33  triggers  IL 13  production  by  murine  eosinophils  in vitro. 
FACS sorted WT and ST2
 /  eosinophils (Siglec F
+CCR3
high) were incubated for 
48h in medium containing GM CSF (1ng/ml, control medium) with or without 
IL 33. IL 13 concentrations in culture supernatants were analyzed by Luminex. 
Data  are  means ± SEM  and  are  representative  of  three  independent 
experiments. *p < 0.05, IL 33 versus control medium.   136 
 
 
 
 
 
 
 
 
 
Fig. 5.12.  IL 33  triggers  IL 6  production  by  murine  eosinophils  in vitro. 
FACS sorted WT and ST2
 /  eosinophils (Siglec F
+CCR3
high) were incubated for 
48h in medium containing GM CSF (1ng/ml, control medium) with or without 
IL 33. IL 6 concentrations in culture supernatants were analyzed by Luminex. 
Data  are  means ± SEM  and  are  representative  of  three  independent 
experiments. *p < 0.05, IL 33 versus control medium. 
* 
* 
p
g
/
m
l
   137 
 
 
 
 
 
 
 
 
 
Fig. 5.13.  IL 33  enhances  TARC  (CCL17)  production  by  murine  eosinophil 
in vitro.  FACS sorted  WT  and  ST2
 /   eosinophils  (Siglec F
+CCR3
high)  were 
incubated for 48h in medium containing GM CSF (1ng/ml, control medium) with 
or without IL 33. CCL17 (TARC) concentrations in culture supernatants were 
analyzed  by  ELISA.  Data  are  means ± SEM  and  are  representative  of  three 
independent experiments. *p < 0.05, IL 33 versus control medium. 
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Fig. 5.14.  IL 33  enhances  TGF b  production  by  murine  eosinophil  in vitro. 
FACS sorted  WT  or  ST2
 /   eosinophils  (Siglec F
+CCR3
high)  were  incubated  for 
48h in medium containing GM CSF (1ng/ml, control medium) with or without 
IL 33. TGF b concentrations in culture supernatants were analyzed by ELISA. 
Data  are  means ± SEM  and  are  representative  of  three  independent 
experiments. *p < 0.05, IL 33 versus control medium. 
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Fig. 5.15.  IL 33  enhances  IgG induced  degranulation  of  mouse  eosinophils 
in vitro. FACS sorted mature eosinophils (Siglec F
+CCR3
high) were pre incubated 
with  GM CSF  or  GM CSF + IL 33  for  24h  before  washed  with  fresh  RPMI 
medium  and  seeded  into  96 well  plates  for  degranulation  assay.  After 
90 minutes  EPO  contents  in  supernatants  was  evaluated.  Cell  viability  was 
assessed by counting in trypan blue. Total EPO release was calculated as the 
percentage  of  total EPO released  from  eosinophils  that  underwent 
3 freeze thaw  cycles.  The  amount  of  EPO  released  from  dead  cells  was 
subtracted  from  the  values  shown.  Data  are  means  (3 technical 
replicates) ± SEM  and  are  representative  of  three  independent  experiments. 
*p < 0.05, IgG1 (1mg/ml) + IL 33 (50ng/ml) versus IgG1 alone (1mg/ml). 
* 
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Fig. 5.16. IL 33 enhances aCD32/16 antibody induced degranulation of mouse 
eosinophils  in vitro.  FACS sorted  mature  eosinophils  (Siglec F
+CCR3
high)  were 
pre incubated  with  GM CSF  or  GM CSF + IL 33  for  24h  before  washed  with 
fresh RPMI medium and seeded  into  96 well plates for degranulation assay. 
After 90 minutes EPO contents in supernatants was evaluated. Cell viability was 
assessed by counting in trypan blue. Total EPO release was calculated as the 
percentage  of  total EPO released  from  eosinophils  that  underwent 
3 freeze thaw  cycles.  The  amount  of  EPO  released  from  dead  cells  was 
subtracted  from  the  values  shown.  Data  are  means  (3 technical 
replicates) ± SEM  and  are  representative  of  three  independent  experiments. 
*p < 0.05;  anti CD32/16  antibody  (1mg/ml) + IL 33  (50ng/ml)  versus 
anti CD32/16 antibody alone (1mg/ml). 
* 
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Fig. 5.17.  IL 33  enhances  aCD32 antibody induced  degranulation  of  human 
eosinophils  in vitro.  Mature  eosinophils  purified  from  peripheral  blood  were 
pre incubated  with  GM CSF  or  GM CSF + IL 33  for  24h  before  washed  with 
fresh RPMI medium and seeded  into  96 well plates for degranulation assay. 
After 90 minutes EPO contents in supernatants was evaluated. Cell viability was 
assessed by counting in trypan blue. Total EPO release was calculated as the 
percentage  of  total EPO released  from  eosinophils  that  underwent 
3 freeze thaw  cycles.  The  amount  of  EPO  released  from  dead  cells  was 
subtracted  from  the  values  shown.  Data  are  means ± SEM  and  are 
representative  of  three  independent  experiments.  *p < 0.05;  anti CD32 
antibody (0.5mg/ml) + IL 33 (50ng/ml) versus anti CD32 antibody alone. 
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Fig. 5.18.  IL 33  enchances  CD32  (FcgII  receptor)  but  not  CD16  (FcgIIIR) 
expression  by  human  eosinophils  in vitro.  Peripheral  blood  eosinophils  were 
enriched  according  to  MACS  Miltenyi  protocol,  pre incubated  with  GM CSF 
(1ng/ml) + IL 33 (10ng/ml) or with GM CSF (1ng/ml) alone (control medium) 
over 24 h and CD32 and CD16 expression was evaluated by FACS. Data are 
representative of three independent experiments.   143 
 
 
 
 
 
 
 
 
 
 
Fig. 5.19.  IL 33 activated  eosinophils  increase  the  differentiation  of 
alternatively  activated  MR
+  but  not  TLR2
+  macrophages  in vitro.  Murine 
macrophages  from  ST2
 /   mice  were  cultured  alone  or  co cultured  with 
FACS sorted  WT  eosinophils  (Siglec F
+CCR3
high)  in  the  presence  of  IL 5 
(5ng/ml)  or  IL 33  (10ng/ml).  After  48h  macrophages  were  stained  with 
anti TLR2 and anti mannose receptor (MR) antibodies. Data are representative 
of three independent experiments. eos = eosinophil; mac = macrophage. 
Isotype   144 
 
 
 
 
 
 
 
 
 
Fig. 5.20.  IL 33 activated  eosinophils  increase  the  percentage  of  MR
+ 
alternatively activated macrophages in vitro. Murine macrophages from ST2
 /  
mice  were  cultured  alone  or  co cultured  with  FACS sorted  WT  eosinophils 
(Siglec F
+CCR3
high) in the presence of IL 5 (5ng/ml) or IL 33 (10ng/ml). After 
48h  macrophages  were  stained  with  anti TLR2  and  anti mannose receptor 
(MR) antibodies.  Data  are  means ± SEM  of  three  independent  experiments 
(n = 3),  *p < 0.05,  eosinophils  + macrophages  + IL 33  versus  other  cultures; 
eos = eosinophil; mac = macrophage.   145 
 
 
 
 
 
 
 
 
 
Fig. 5.21.  The  IL 33 triggered  macrophage  switching  to  AAM  phenotype  is 
dependent on IL 13 (representative FACS results). Murine macrophages from 
ST2
 /   mice  were  co cultured  with  FACS sorted  WT  eosinophils 
(Siglec F
+CCR3
high)  in  the  presence  of  IL 33  (10ng/ml)  or  IL 33 
(10ng/ml) + anti IL 13 Ab or isotype control (10mg/ml). After 48h macrophages 
were stained with anti TLR2 and anti mannose receptor (MR) antibodies. The 
IL 33 induced increase in MR
+ macrophages markedly blocked by anti IL 13 Ab. 
Data are representative of three independent experiments. Eos = eosinophil; 
Mac = macrophage. 
Isotype 
                          Mac + eos + IL 33 
                 IgG                             anti IL 13 Abs 
TLR2 
M
R
   146 
 
 
 
 
 
 
 
 
 
Fig. 5.22.  The  IL 33 triggered  macrophage  switching  to  AAM  phenotype  is 
dependent on IL 13 (quantitative data). Murine macrophages from ST2
 /  mice 
were  co cultured  with  FACS sorted  WT  eosinophils  (Siglec F
+CCR3
high)  in  the 
presence  of  IL 33  (10ng/ml)  or  IL 33  (10ng/ml) + anti IL 13 Ab  or  isotype 
control  (10mg/ml).  After  48h  macrophages  were  stained  with  anti TLR2  and 
anti mannose receptor  (MR) antibodies.  Data  are  means ± SEM  of  three 
independent  experiments  (n = 3), 
#p < 0.05,  eosinophils + anti IL 13  versus 
eosinophils + IgG. Eos = eosinophil.   147 
 
 
 
 
 
 
 
Fig. 5.23.  IL 33  increases  CD69  expression  on  human  eosinophils 
(representative  FACS  results).  PB eosinophils  were  cultured  in  complete 
medium  or  in  medium  complemented  with  IL 5  (10ng/ml)  or  IL 33  (10  or 
50ng/ml) for 48hours, followed by surface FACS staining for CD69 and ST2L. 
Results representative of 6 donors of 3 independent experiments are shown. 
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Fig. 5.24. IL 33 increases CD69 expression on human eosinophils (quantitative 
data).  Human  eosinophils  were  cultured  in  complete  medium  or  in  medium 
complemented with IL 5 (10ng/ml) or IL 33 (10 or 50ng/ml) for 48h, followed 
by surface FACS staining for CD69. Data are means ± SEM of 6 donors.   149 
 
 
 
 
 
 
 
Chapter 6: 
The role of IL-33-activated eosinophils 
 in airway inflammation   150 
6.1.  The contribution of IL-33-activated eosinophils to 
airway inflammation 
Given the role of the IL 33/ST2L system in eosinophil activation in vitro, I next 
investigated  the  contribution  of  IL 33 activated  eosinophils  to  airway 
inflammation.  FACS sorted  WT  eosinophils  (CCR3
high Siglec F
+)  were  stained 
with  CFSE  and  adoptively  transferred  i.n.  into  ST2
 /   mice.  Subsequently, 
recipients received IL 33 or PBS i.n. for 3 consecutive days. Mice were culled 
24h  after  the  last  IL 33 challenge  and  BAL fluid  and  cells  were  analyzed. 
Differential  cell  counts  confirmed  the  presence  of  eosinophils  in  mice  that 
received cells and a complete lack of eosinophils in the control groups given 
IL 33  or  PBS  only  (Fig. 6.1.).  Mice  that  received  eosinophils  plus  IL 33 
exhibited markedly  higher total cell,  eosinophil, macrophage  and lymphocyte 
counts than those that received eosinophils plus PBS. BAL from the recipients of 
eosinophils  plus  IL 33  also  contained  significantly  higher  numbers  of  host 
eosinophils (CFSE
 ) than the group given eosinophils plus PBS (Figure 6.1.). 
Moreover,  IL 33 activated  eosinophils  increased  CD4  T cell  infiltration  of  the 
recipients’ lungs as measured by FACS (Figure 6.2.). These data indicate that 
adoptively  transferred  eosinophils  stimulated  with  IL 33  have  a  potential  to 
exacerbate airway inflammation.   151 
6.2.  The contribution of IL-33-activated eosinophils to airway 
cytokine expression levels 
Data  presented  in  the  section  above  suggest  that  IL 33,  given  to 
IL 33 unresponsive  (ST2
 / )  recipients,  that  had  received  WT  eosinophils, 
induced the production of mediators that were likely responsible for attracting 
recipients’  inflammatory  cells  into  the  lungs.  To  further  test  this  hypothesis 
I checked BAL fluids for the presence of cytokines and chemokines. BAL fluid 
analysis showed that, in contrast to animals that received PBS and IL 33 alone, 
both recipient groups that received eosinophils showed the presence of TARC 
(CCL17), MIP 1a (CCL3), eotaxin (CCL11), eotaxin 2 (CCL24), IL 13 and TGF b 
(Figure 6.3.).  However,  mice  that  received  eosinophils  plus  IL 33  produced 
significantly  more  CCL17,  IL 13,  TGF b,  CCL3  and  CCL24  than  those  given 
eosinophils  with  PBS  (Figure 6.3.).  These  data  suggest  that  IL 33 activated 
eosinophils can indeed be a potent source of inflammatory mediators in the 
airways. 
 
6.3.  The effect of IL-33-activated eosinophils on the 
phenotype of alveolar macrophages 
In section 5.3.3. I showed that IL 33 activated eosinophils were able to induce 
differentiation of BM derived macrophages into M2, AAM in co cultures in vitro. 
Having  found  an  increased  number  of  macrophages  in  BAL  from  mice  that 
received  eosinophils  plus  IL 33  I  was  interested  in  the  actual  phenotype  of   152 
these alveolar macrophages. To investigate this I stained BAL cells for F4/80, 
CCR3,  MR,  and  TLR2.  Alveolar  macrophages  from  control  mice  had  low 
expression of MR (a marker of M2 macrophage) that was consistent with their 
quiescent phenotype (26). The presence of adoptively transferred eosinophils in 
the  airways  increased  the  percentage  of  F4/80
+CCR3
   MR
+  macrophages. 
However,  mice  that  received  eosinophils + IL 33  had  a  significantly  higher 
proportion  of  MR
+  macrophages  than  mice  that  received  eosinophils + PBS 
(Figure 6.4.). The percent of TLR2
+ (a marker of M1) macrophages was low 
and there was no difference between  the groups (Figure 6.5.). These data 
therefore  indicate  that  IL 33 activated  eosinophils  can  increase  the 
differentiation of alveolar macrophages toward the M2 phenotype in vivo. 
Summary of Chapter 6 
In summary, data presented in this chapter demonstrate that IL 33 activated 
eosinophils  can  significantly  contribute  to  airway  inflammation  by  releasing 
cytokines/chemokines, attracting other inflammatory cells and supporting the 
differentiation of alveolar macrophages towards M2, AAM.   153 
 
 
 
 
 
 
 
 
Fig. 6.1.  Adoptive  transfer  of  IL 33 activated  eosinophils  results  in  the 
infiltration of the airways by ST2
 /  recipients’ inflammatory cells. FACS sorted 
WT eosinophils (Siglec F
+ CCR3
high, 10x10
6/mouse) were stained with CFSE and 
adoptively  transferred  i.n.  into  ST2
 /   recipients  that  were  subsequently 
administered  IL 33  for  3 days  i.n.  Control  groups  received  eosinophils +PBS, 
PBS  alone  or  IL 33  alone.  Mice  were  culled  24 h  after  the  last  IL 33 
administration.  BAL  fluid  differential  cell  counts  are  shown.  Data  are 
means ± SEM  (n = 5 mice/group)  and  are  representative  of  two  independent 
experiments;  *p < 0.05,  eosinophils  versus  PBS  or  IL 33  alone 
#p < 0.05, 
eosinophils + IL 33 versus eosinophils + PBS. Eos = eosinophils; Recipients’ Eos 
= CFSE negative eosinophils. 
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Fig. 6.2.  IL 33  activated  eosinophils  attract  CD4  T  cells.  FACS sorted  WT 
eosinophils  (Siglec F
+CCR3
high)  were  stained  with  CFSE  and  adoptively 
transferred i.n. into ST2
 /  recipients that were subsequently administered IL 33 
or  PBS  daily  for  3 days  i.n.  Mice  were  culled  24h  following  the  last  IL 33 
aministration. FACS staining for CD4  is shown. Data  are representative of 5 
mice with similar results. Eos = eosinophil.   155 
 
 
 
 
 
 
 
 
Fig. 6.3.  Adoptively  transferred  IL 33 activated  eosinophils  induce 
inflammatory cytokine and chemokine production in the lungs of ST2
 /  recipient 
mice.  FACS sorted  WT  eosinophils  (Siglec F
+CCR3
high)  were  adoptively 
transferred i.n. into ST2
 /  recipients that were subsequently administered IL 33 
for 3 days i.n. Control groups received eosinophils +PBS, PBS alone or IL 33 
alone. Mice were culled 24h after the last IL 33 administration. Cytokine and 
chemokine concentrations measured in BAL fluid by ELISA are shown. Data are 
means ± SEM  (n = 5 mice/group)  and  are  representative  of  two  independent 
experiments;  *p < 0.05,  eosinophils  versus  PBS  or  IL 33  alone; 
#p < 0.05,  eosinophils + IL 33  versus eosinophils + PBS; Eos = eosinophils 
TARC 
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Fig. 6.4. Adoptively transferred IL 33 activated eosinophils markedly increase 
the proportion of alternatively activated macrophages (M2, AAM) in the lungs of 
ST2
 /   recipient  mice.  FACS sorted  WT  eosinophils  (Siglec F
+CCR3
high)  were 
stained with CFSE and adoptively transferred i.n. into ST2
 /  recipients that were 
subsequently  administered  IL 33  for  3 days  i.n.  Control  groups  received 
eosinophils +PBS, PBS alone or IL 33 alone. Mice were culled 24h after the last 
IL 33 administration. MR expression on BAL fluid macrophages (F4/80
+CCR3
 ) is 
shown.  Data  are  means ± SEM  (n = 5 mice/group)  and  are  representative  of 
two  independent  experiments;  *p < 0.05,  eosinophils  versus  PBS  or  IL 33 
alone;  #p < 0.05,  eosinophils + IL 33  versus  eosinophils + PBS;  Eos = 
eosinophils. 
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Fig. 6.5. IL 33 activated eosinophils do not alter the proportion of classically 
activated macrophages (M1) in the lungs of ST2
 /  recipient mice. FACS sorted 
WT eosinophils (Siglec F
+CCR3
high) were adoptively transferred i.n. into ST2
 /  
recipients  that  were  subsequently  administered  IL 33  for  3 days  i.n.  Control 
groups received eosinophils +PBS, PBS alone or IL 33 alone. Mice were culled 
24h  after  the  last  IL 33  administration.  TLR2  expression  on  BAL  fluid 
macrophages  (F4/80
+CCR3
 )  is  shown.  Data  are  means ± SEM 
(n = 5 mice/group)  and  are  representative  of  two  independent  experiments; 
Eos = eosinophils. 
Macrophages   158 
 
 
 
 
 
 
 
Chapter 7: 
Discussion   159 
Latterly, IL 33 has been implicated in type 2 lung inflammation mainly for its 
ability  to  affect  T cell  activation  (80).  However,  the  role  of  IL 33  in  innate 
immune response in the lungs remains largely unknown. Studies in vivo showed 
that  mast  cells,  basophils  and  NK  cells  are  not  essential  for  IL 33 induced 
airway inflammation ((185) and Pitman, N. et al., unpublished data).  
It  was  recently  demonstrated  that  IL 33  can  be  released  from  naïve  lung 
explants  upon  stimulation  with  LPS  and  alum,  likely  via  NLRP3 mediated 
inflammasome activation (15). A study from our laboratory reported that IL 33 
protein  is  detected  in  the  lungs  of  mice  with  OVA/alum induced  airway 
inflammation (43). Furthermore, immunohistochemistry studies carried out in 
our  laboratory  revealed  that  lung  biopsies  from  asthma  patients  exhibit 
markedly  elevated  IL 33  expression  in  bronchial  epithelial  cells  compared  to 
healthy  individuals,  although  a  baseline  IL 33  expression  was  observed  in 
healthy  controls  as  well.  These  data,  in  conjunction  with  recent  reports 
suggesting that IL 33 can be rapidly released from epithelial cells in response to 
tissue injury or infection (6) seem to imply that IL 33 may play an important 
role in the pathogenesis of asthma, through the activation of lung resident cells 
that  are  readily  expressing  IL 33R,  such  as  epithelial  cells,  fibroblasts  and 
alveolar macrophages.  
Indeed, the latest study into the role of IL 33 in airway inflammation carried out 
in  our  laboratory  (26)  confirmed  early  reports  (4,  48)  that  IL 33  induces 
massive  airway  inflammation  manifested  by  eosinophil  and  macrophage 
infiltration of the lung tissue and BAL fluid, as well as markedly elevated local   160 
concentrations  of  IL 5  and  IL 13  and  induced  goblet  cell  hyperplasia.  Most 
intriguingly,  our  study  revealed  a  significant  alteration  to  the  quiescent 
phenotype of alveolar macrophages from IL 33 treated mice which exhibited a 
profound increase in the expression of mannose receptor and IL 4Ra, as well as 
produced Eotaxin 2 and TARC which together constitute the characteristics of 
alternatively  activated  macrophages  (M2,  AAM).  Moreover,  we  demonstrated 
previously that the differentiation of AAM was IL 33/ST2 dependent and also 
required IL 13/IL 4Ra but not IL 4 (26). AAM contributed to the IL 33 induced 
innate type 2 inflammation in the lungs by releasing chemokines, particularly 
Eotaxin 2  which  neutralization  reduced  IL 33  triggered  airway  inflammation 
(26). 
In order to confirm the role that alternatively activated alveolar macrophages 
play in IL 33 induced airway inflammation I employed a technique designed by 
Thepen  et  al.  (157)  which  allows for  the  depletion  of  alveolar  macrophages 
in vivo  by  means  of  intranasal  administration  of  clodronate containing 
liposomes  that  specifically  target  alveolar  macrophages  (Figure 2.2.).  I  was 
able to show that elimination of macrophages from the alveolar space leads to 
the amelioration of the IL 33 induced inflammation as reflected by decreased 
total BAL cell counts, as well as eosinophil counts in clodronate treated mice 
compared to PBS control (Figure 3.2.). Furthermore, I provided an insight into 
the  mechanism  by  which  IL 33  induces  the  differentiation  of  of  alveolar 
macrophages  toward  AAM  and  thus  inducing  airway  inflammation  by 
demonstrating  that  IL 13  signaling  pathway  plays  an  essential  role  in  this   161 
process  and  its  disruption  significantly  ameliorates  IL 33 induced  airway 
inflammation (Figure 3.3.). 
By  releasing  chemokines,  in  particular  eotaxin 2  (CCL24)  (26),  alveolar 
macrophages constitute a link between lung resident cells that act as the first 
line of response to IL 33 and several other cell types of the immune system, 
such  as  eosinophils,  basophils  mast  cells  and  T  cells,  all  of  which  can  be 
recruited  into  the  lungs  and  contribute  to  the  IL 33 induced  airway 
inflammation. 
Given the prominent role of eosinophil leukocyte in asthma pathogenesis (186), 
in conjunction with more recent studies demonstrating that human eosinophils 
are able to express IL 33R (ST2L) in vitro (187), the contribution of IL 33/ST2 
pathway to eosinophil differentiation and activation during the course of airway 
inflammation required further clarification. 
Enhanced eosinophil differentiation is a hallmark feature of most clinical and 
experimental asthma phenotypes (143, 188) as well as IL 33 induced airway 
inflammation  as  demonstrated  here  and  elsewhere  (4,  48).  Data  obtained 
during  this  project  indicate  that  IL 33  can  act  directly  on  bone  marrow 
CD117
+ST2L
+  hematopoietic  precursor  cells  and  induce  their  differentiation 
toward  eosinophils.  This  process  depends  on  IL 5  and  is  IL 9  and  IL 13 
independent.  Thus,  IL 33 driven  eosinophilia  is  likely  a  consequence  of  the 
cooperative  autocrine  action  of  IL 5  produced  by  CD117
+  hematopoietic 
precursors themselves that leads to their differentiation to eosinophils in bone   162 
marrow, and the effect of IL 5 and/or chemokines produced by the cells on the 
periphery  (4,  26,  29,  43)  that  mobilize  mature  eosinophils  from  the  bone 
marrow  compartment  to  the  inflamed  tissue.  Further  studies  are  needed  to 
identify which progenitor cell population responds to IL 33 as both CMP and 
GMP express CD117 (90) (see Figure 1.3.). 
Consistent  with  the  above  findings,  recent  study  demonstrated  that  human 
hematopoietic CD34
+ cells from asthma patients express ST2L and respond to 
IL 33 by IL 5 production (189). This raises a possibility that IL 33 may drive 
eosinophil differentiation from hematopoietic precursors in clinical settings.  
Furthermore,  I  show  here  that  IL 33/ST2  system is  essential  for  an  optimal 
expression of CCR3 by differentiating eosinophils. It is well documented that 
CCR3 is of particular importance for eosinophil biology as it combines its action 
with  IL 5  to  facilitate  mobilization  of  eosinophils  from  bone  marrow  to 
peripheral blood and it is ultimately responsible for eosinophil trafficking into 
the sites of inflammation (190). The lack of an optimal expression of CCR3 on 
ST2
 /  eosinophils can likely be responsible for a decreased number of recruited 
eosinophils in BAL of ST2
 /  compared to WT mice during OVA induced airway 
inflammation model (Figure 5.10.), (26, 43). Of note, and in agreement with 
recent studies (191), IL 33 did not affect CCR3 expression on eosinophils that 
are already in the periphery (data not shown) or at sites of inflammation. 
The accumulation of eosinophils in the airways is a prominent feature of most 
clinical  asthma  subtypes  and  experimental  asthma  models  (143,  188).  Many   163 
human and animal studies point out the important function of eosinophils in the 
exacerbation  of  lung  disease  and  airway  remodeling  (143).  However,  the 
precise factors that are responsible for the localized activation of eosinophils in 
the  asthmatic  lungs  are  not  fully  recognized.  This  become  of  particular 
importance  in  the  light  of  recent  finding  that  airway  eosinophils  are  not 
susceptible to IL 5 as they shed their surface IL 5 receptor while they enter 
airway  lumen  (166).  Given  the  abundant  expression  of  IL 33  in  the stromal 
tissue of asthmatic lungs (26 27), the possibility arises that IL 33 may trigger 
the activation of eosinophils that have been recruited to the airways. 
Consistent with data published previously (191 192), I found that only limited 
proportion  of  mature  mouse  and  PB  eosinophils  of  most  human  donors 
expressed ST2L although they did express mRNA for both ST2L and sST2. By 
contrast, eosinophils that accumulated in airways during OVA induced asthma 
model  did  express  high  levels  of  ST2L  on  the  surface.  My  in vitro  studies 
revealed that both IL 33 itself and GM CSF are likely to upregulate ST2L on 
airway eosinophils. Intriguingly, IL 5 seems to play an inhibitory role in ST2L 
expression  if  acting  alone  on  human  eosinophils.  This  might  prevent  the 
activation of eosinophils driven by constitutive low levels of IL 5, GM CSF and 
IL 3, which may be present under normal steady state conditions. 
The observation that in two out of six human donors PB eosinophils exhibited 
readily  detectable  ST2L  expression  could  be  attributed  to  the  mild  ongoing 
allergic  reactions  in  those  subjects.  However,  further  studies  in  a  bigger 
population of clinically diagnosed allergic individuals and healthy subjects are   164 
required in order to establish a true variation of ST2L expression in human PB 
eosinophis. 
Recent  studies  on  eosinophil  deficient  mice  show  an  important  role  of 
eosinophils  in  cytokine  and  chemokine  production,  and  thereby  their 
contribution to the perpetuation of inflammation (110, 145). Here, I show that 
IL 33  can  be  a  trigger  of  these  processes.  IL 33/ST2 activated  eosinophils 
contribute  to  the  exacerbation  of  inflammation  by  increasing  the  number  of 
macrophages  and  lymphocytes  in  the  lungs  which  can  be  attributed  to  the 
increase in levels of cytokines and chemokines, including TARC, IL 13, TGF b, 
MIP 1a and Eotaxin 2. My in vitro data show that murine eosinophils can be a 
potent  source  of  TARC,  IL 13,  IL 6  and  TGF b  upon  IL 33  stimulation. 
Interestingly,  pulmonary,  eosinophil dependent  TARC  release  appears  to  be 
required for the localized recruitment of effector T cells during asthma model 
(145). I was able to demonstrate that IL 33 can be a factor that drives TARC 
production by eosinophils and this is followed by the accumulation of CD4 cells 
in the airways. 
IL 33 in vitro seemed to have no effect on eotaxin 2 and MIP 1a production by 
eosinophils themselves. Thus, elevated levels of these two chemokines found in 
BAL  of  ST2
 /   recipients  that  received  WT  eosinophil  cells  followed  by  IL 33 
injection are probably due to an indirect effect of IL 33 stimulated eosinophils 
interacting  with  other  cell  population  in  the  lungs,  such  as  alveolar 
macrophages. In fact, the very presence of eosinophils in the airways triggers 
the differentiation of quiescent alveolar macrophages towards MR
+ alternatively   165 
activated macrophages, a phenotype that is pathogenic in type 2 diseases (26, 
150). Studies focused on a mechanism behind this process revealed that IL 13, 
which  is  a  well  known  AAM  differentiation  factor  that  is  also  released  by 
eosinophils upon IL 33 stimulation can be, at least partially, responsible for the 
increased differentiation of AAM macrophages. Consistent with our data, Rankin 
et al. demonstrated that IL 33 induces the production of IL 13 from eosinophils 
which,  in  turn,  can  promote  the  development  of  cutaneous  fibrosis  (193). 
Moreover,  the  elegant  studies  by  Pope  et  al.  and  Kurowska Stolarska  et  al. 
suggest that BAL AAM macrophages may be the major producers of Eotaxin 2 
in  experimental  asthma  model  (26,  127).  Thus,  it  is  likely  that  AAM  are 
responsible  for  the  elevated  levels  of  Eotaxin 2  that  I  could  observed  in 
recipients given eosinophils plus IL 33.  
There is growing evidence to support the notion that eosinophils also have the 
capacity  to  regulate  mast  cell  function,  which  are  producers  of  an  array  of 
chemokines, including MIP 1a (130, 194). Therefore; lung resident mast cells 
may likely release MIP 1a upon interaction with IL 33 activated eosinophils.  
Furthermore,  IL 33 activated  WT  eosinophils,  consistent  with  the  BAL 
chemokine  profile  they  contribute  to,  could  attract  more  host  (ST2
 / ) 
eosinophils to the airways. Intriguingly, administration of IL 33 locally into the 
lungs  also  helped  maintain  significant  numbers  of  adoptively  transferred 
eosinophils in the airways. This may be explained by the effect of IL 33 induced 
chemokines that lock those cells in the airways. Furthermore, the survival of 
adoptively transferred eosinophils may be enhanced  either as a result of an   166 
interaction with other cells or as a direct effect of IL 33. The latter possibility is 
supported by observations in human eosinophils in vitro (187, 191 192). 
Finally,  my  work  provides  evidence  that  IL 33  can  significantly  increase  the 
eosinophil susceptibility to antibody triggered degranulation by increasing the 
expression the expression of FcgIIR (CD32). Thus, the release of IL 33 from 
inflamed  tissue  may  be  a  crucial  factor  responsible  for  cytotoxic 
granule mediated tissue damage in clinical settings. In contrast to other studies 
(187), I did not detect any substantial eosinophil degranulation in the presence 
of IL 33 or IL 5 alone. In support of my findings, numerous studies suggest 
that cytokines, such as IL 5 for example, also have a limited contribution to the 
degranulation  process,  compared  to  potent  degranulation  factors  such  as 
immuno complexes or complement molecules (195 196). 
Taken  together,  IL 33/ST2  pathway  regulates  multiple  features of  eosinophil 
biology that can have a significant impact on allergic inflammation and asthma. 
In  this  project,  I  show  that  IL 33  can  directly  differentiate  eosinophils  from 
bone  marrow  precursors.  Most  importantly,  I  demonstrate  that  mature 
eosinophils can acquire high levels of IL 33 receptor (ST2L) at sites of airway 
inflammation. Finally my work provides new evidence that eosinophils activated 
through  the  IL 33/ST2  signaling  pathway  play  an  important  role  in  airway 
inflammation  in vivo.  A  possible  mechanism  by  which  IL 33  activates 
eosinophils  and  their  contribution  to  airway  inflammation  is  summarized  in 
Figure 7.1.    167 
Given the limited benefit of anti IL 5 therapy in asthma patients, reflected by 
only moderate decrease in sputum eosinophil counts (only 55% reduction) and 
lack of clinical benefit (197 198), inhibition of the IL 33/ST2 pathway can be 
considered  a  promising  therapeutic  target.  This  notion  is  supported  by  an 
increasing  number  of  studies  showing  that  IL 33/ST2  pathway  is  equally 
important in the activation of other cell types involved in the pathogenesis of 
allergy and asthma, such as Th2 cells, mast cells, DC and macrophages (4, 26, 
29, 43, 48, 68).   168 
Figure 7.1.  The  contribution  of  IL 33 induced  eosinophils  to  airway 
inflammation 
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